Protocol CVL -751-PD-003 
Tavapadon  
Confidential  Page 1 of 90 Version  4.0: 06 Jul 2023      
CLINICAL PROTOCOL  
A PHASE 3, DOUBLE -BLIND, RANDOMIZED, 
PLACEBO -CONTROLLED, PARALLEL -GROUP, 
FLEXIBLE -DOSE, 27 -WEEK TRIAL TO EVALUATE THE 
EFFICACY, SAFETY, AND TOLERABILITY OF TAVAPADON AS 
ADJUNCTIVE THERAPY FOR PARKINSON’S  DISEASE IN 
LEVODOPA -TREATED ADULTS  
WITH MOTOR FLUCTUATIONS (T EMPO-3 TRIAL)  
Protocol Number: CVL -751-PD-003 
Compound: Tavapadon (CVL -751) 
Trial Phase: 3  
Short Title: Flexible -Dose, Adjunctive Therapy Trial in Adults Wit h Parkinson’s 
Disease With Motor Fluctuations  
Sponsor Name: [CONTACT_308719], LLC  
Legal Registered Address: [ADDRESS_683102], Cambridge, MA [ZIP_CODE] [LOCATION_003]  
Regulatory Agency Identifier Number  
Regulatory Agency File  Identifying #  
IND 118,[ADDRESS_683103]  2019 -002951 -40 
Version 4.0: 06 Jul 2023  
Version 3.0: 03 Sep 2021  
Version 2.0: 29  Jun 2020  
Original Version 1.0: [ADDRESS_683104] INFORMATION ARE PROVIDED 
IN THE TRIAL OPERATIONS MANUAL.  
[STUDY_ID_REMOVED]
  
Protocol CVL -751-PD-003 
Tavapadon  
 
Confidential  Page 3 of 90 Version  4.0: 06 Jul 2023      
PROTOCOL VERSION 4.0 SUMMARY OF CHANGES TABLE  
Document History  
Document:  Date (Day -Month -Year)  
Version 4.[ADDRESS_683105] 2019  
Amendment: Protocol Version 4.0 ( 06 Jul 2023)  
This amendment is considered to be  substantial based on the criteria set forth in Article 
10(a) of Directive 2001/20/EC of the European Parliament and the Council of the 
European Union.  
Overall Rationale for the Amendment: The overall rationale for this amendment is to 
add eye examinations  as an additional trial assessment to monitor for the new potential 
risk of increased intraocular pressure across the Phase 3 tavapadon protocols.  
 
Section # and Name  [CONTACT_11029]  
1.3 Schedule of Assessments  Added eye examination assessment   
Added footnote s “w” and “x” to 
clarify the assessment and follow -up 
frequency  To monitor for increased 
intraocular pressure  
 Removed footnote “b” allowing 
remote visits if the subject cannot 
attend the clinic visit in person due 
to restrictions related to COVID -[ADDRESS_683106] ended  
8.3.8 Eye Examinations  Added new section for eye 
examinations and guidance for 
follow -up To monitor for increased 
intraocular pressure  
 
  
Protocol CVL -751-PD-003 
Tavapadon  
 
Confidential  Page 4 of 90 Version  4.0: 06 Jul 2023      
TABLE OF CONTENTS  
 
PROTOCOL VERSION 4.0  SUMMARY OF CHANGES TABLE  ............................. 3 
TABLE OF CONTENTS  ................................ ................................ ................................ ..4 
TABLE OF TABLES  ................................ ................................ ................................ ......... 7 
TABLE OF FIGURES  ................................ ................................ ................................ .......7 
1 PROTOCOL S UMMARY  ................................ ................................ ......................... 8 
1.1 Synopsis  ................................ ................................ ................................ ................... 8 
1.2 Schema  ................................ ................................ ................................ .................. 12 
1.3 Schedule of As sessments  ................................ ................................ ...................... 12 
2 INTRODUCTION  ................................ ................................ ................................ ....17 
2.1 Trial Rationale  ................................ ................................ ................................ .....17 
2.2 Back ground  ................................ ................................ ................................ .......... 17 
2.3 Benefit/Risk Assessment  ................................ ................................ ...................... 19 
3 OBJECTIVES AND ENDPO INTS  ................................ ................................ ......... 21 
4 TRIAL DESIGN  ................................ ................................ ................................ .......22 
4.1 Overall Design  ................................ ................................ ................................ ......22 
4.1.1  Screening/Baseline Period  ................................ ................................ ............. [ADDRESS_683107] ................................ ................................ ......... 26 
4.5 End of Trial Definition  ................................ ................................ ........................ 26 
5 TRIAL POPULATION  ................................ ................................ ............................ 26 
5.1 Inclusion Criteria  ................................ ................................ ................................ .26 
5.2 Exclusion Criteria  ................................ ................................ ................................ 27 
5.3 Lifestyle Considerations  ................................ ................................ ...................... 30 
5.4 Screen Failures  ................................ ................................ ................................ .....30 
6 TRIAL TREATMENTS  ................................ ................................ ........................... 31 
6.1 Trial Intervention(s) Administered  ................................ ................................ ....31 
6.2 Preparation/Handling/Storage/Accountability  ................................ ................. 31 
6.3 Measures to Minimize Bias: Randomization and Blinding .............................. [ADDRESS_683108] 
DISCONTINUATION/WITH DRAWAL  ................................ ............................... 37 
  
Protocol CVL -751-PD-003 
Tavapadon  
 
Confidential  Page 5 of 90 Version  4.0: [ADDRESS_683109] to Follow up  ................................ ................................ ................................ ..39 
8 TRIAL ASSESSMENTS AN D PROCEDURES  ................................ .................... 39 
8.1 Screening and Baseline Assessments  ................................ ................................ ..40 
8.2 Efficacy Assessments  ................................ ................................ ........................... 41 
8.2.1 Hauser Diary  ................................ ................................ ................................ ..41 
8.2.2  Movement Disorder Society -Unified Parkinson’s Disease Rating 
Scale  ................................ ................................ ................................ ................. 41 
8.2.3  39-Item Parkinson’s Disease Questionnaire  ................................ ................ 42 
8.2.4  EuroQol 5 Dimension 5 Level  ................................ ................................ .......42 
8.3 Safety Assessments  ................................ ................................ ............................... 43 
8.3.1  Epworth Sleepi[INVESTIGATOR_7110]  ................................ ................................ .............. 43 
8.3.2  Questionnaire for Impulsive -Compulsive Disorders in Parkinson’s 
Disease -Rating Scale  ................................ ................................ ...................... [ADDRESS_683110]  ................................ ................................ ................................ .....48 
8.4.1  Time Period and Frequency for Collecting AE and SAE/AESI 
Information  ................................ ................................ ................................ .....48 
8.4.2  Method of Detecting AEs and SAEs/AESI  ................................ .................. 48 
8.4.3  Follow -up of AEs and SAEs/AESI ................................ ................................ 48 
8.4.4  Regulatory Reporting Requirements for SAEs/AESI  ................................ [ADDRESS_683111]  ................................ ............................... 49 
8.5 Treatment of Overdose  ................................ ................................ ........................ 51 
8.6 Pharmacokinetics  ................................ ................................ ................................ .51 
8.7 Futu re Biospecimen Research  ................................ ................................ ............ 52 
9 STATISTICAL CONSIDER ATIONS  ................................ ................................ ....52 
9.1 Statistical Hypotheses  ................................ ................................ .......................... 52 
9.2 Sample Size Determination  ................................ ................................ ................. 52 
9.3 Populations for Analyses  ................................ ................................ ..................... 52 
9.4 Statistical Analyses ................................ ................................ ............................... 53 
9.4.1  Efficacy Analyses  ................................ ................................ ........................... 53 
9.4.2 Safety Analyses  ................................ ................................ ............................... 55 
9.4.3  Other Analyses  ................................ ................................ ............................... 56 
9.5 Interim Analysis  ................................ ................................ ................................ ...56 
10 SUPPO RTING DOCUMENTATION AND OPERATIONAL 
CONSIDERATIONS  ................................ ................................ ................................ 57 
10.1  Appendix 1: Regulatory, Ethical, and Trial Oversight Considerations  ......... 57 

  
Protocol CVL -751-PD-003 
Tavapadon  
 
Confidential  Page 6 of 90 Version  4.0: 06 Jul 2023      
10.1.1  Regulatory and Ethical Considerations  ................................ ....................... 57 
10.1.2  Financial Disclosure  ................................ ................................ ....................... 57 
10.1.3  Informed Consent Process  ................................ ................................ ............ 58 
10.1.4  Data Protection ................................ ................................ ............................... 58 
10.1.5  Dissemination of Clinical Trial Data  ................................ ............................ 58 
10.1.6  Data Quality Assurance  ................................ ................................ ................. 59 
10.1.7  Source Documents  ................................ ................................ .......................... 60 
10.1.8  Trial and Site Closure  ................................ ................................ .................... 60 
10.1.9  Publication Policy ................................ ................................ ........................... 61 
10.2  Appendix 2: Clinical Laboratory Tests ................................ .............................. 62 
10.3  Appendix 3: Adverse Events: Definitions and Procedures for 
Recording, Evaluating, Follow -up, and Reporting  ................................ ........... 64 
10.3.1  Definition of AE ................................ ................................ .............................. 64 
10.3.2 Definition of SAE  ................................ ................................ ........................... 64 
10.3.3  Recording and Follow -Up of AEs and/or SAEs/AESI  ................................ 66 
10.3.4  Reporting of SAEs/AESI  ................................ ................................ ............... 68 
10.4  Appendix 4: Contraceptive Guidance and Collection of Pregnancy 
Information  ................................ ................................ ................................ ........... 70 
10.4.1  Definitions  ................................ ................................ ................................ .......70 
10.4.2  Collection of Pregnancy Information  ................................ ........................... 71 
10.5  Appendix 5: Future Biospecimen Research  ................................ ...................... 73 
10.6  Appendix  6: Examples of Moderate and Strong Inducers and 
Inhibitors of Cytochrome P450 3a (CYP3A)  ................................ ..................... 74 
10.7  Appendix 7: Abbreviations  ................................ ................................ ................. 76 
10.8  Appendix  8: Protocol Amendment History  ................................ ....................... 79 
11 REFERENCES  ................................ ................................ ................................ ......... 87 
CLINICAL PROTOCOL PR INCIPAL INVESTIGATOR  
SIGNATURE  [CONTACT_1783]  ................................ ................................ ................................ 90 
 
  
Protocol CVL -751-PD-003 
Tavapadon  
 
Confidential  Page 7 of 90 Version  4.0: [ADDRESS_683112] of Medications Prohibited During the Trial  ................................ ..36 
Table  8 Populations for Analysis  ................................ ................................ .......... 53 
Table  9 Efficacy Analysis  ................................ ................................ ...................... 55 
Table  10 Safety Analysis  ................................ ................................ ......................... 56 
Table  11 Protocol -Required Safety Laboratory Assessments  ............................. 62 
Table  12 Definition of AE ................................ ................................ ........................ 64 
Table  13 Events Meeting the AE Definition  ................................ .......................... 64 
Table  14 Definition of SAE  ................................ ................................ ..................... 65 
Table  15 Recording of AEs and/or SAEs/AESI  ................................ .................... 66 
Table  16 Follow -Up of AEs and SAEs/AESI  ................................ ......................... 68 
Table 17  SAE/AESI Reporting to the Sponsor or Designee via an Electronic  
Data Collection Tool  ................................ ................................ ................ 68 
Table  18 SAE/AESI Reporting to Sponsor or Designee via Paper CRF 
(If Needed)  ................................ ................................ ................................ 69 
Table 19  Examples of Moderate and Strong Inducers and Inhibitors of CYP3A
................................ ................................ ................................ .................... 74 
 
TABLE OF FIGURES  
Figure  1 Trial Schematic  ................................ ................................ ........................ 12 
 
  
Protocol CVL -751-PD-003 
Tavapadon  
 
Confidential  Page 8 of 90 Version  4.0: 06 Jul 2023      
1 PROTOCOL SUMMARY  
1.1 Synopsis  
Sponsor Name: [CONTACT_308719], LLC  
Name [CONTACT_92732]:  Tavapadon  
Protocol Title: A Phase 3, Double -Blind, Randomized, Placebo -Controlled, 
Parallel -Group, Flexible -Dose, 27 -Week Trial to Evaluate the Efficacy, Safety, and 
Tolerability of Tavapadon as Adjunctive Therapy for Parkinson’s Disease in 
Levodopa -Treated Adults With Motor Fluctuations (T EMPO-3 Trial)  
Short Title: Flexible -Dose, Adjunctive Therapy Trial in Adults With Parkinson’s 
Disease With Motor Fluctuations  
IND Number:  118,[ADDRESS_683113] Number:  2019 -002951 -40 
Trial Phase: 3 
Indication: Parkinson’s disease  
Rationale: Tavapadon (PF -06649751, CVL -751) is a partial ag onist of the dopamine 
D1-like receptors (D1Rs), with high specificity for the D1 and D5 receptor subtypes 
(D1/D5), which is being developed as a treatment for Parkinson's disease (PD). The 
efficacy, safety, and tolerability of tavapadon in Phase  1b and [ADDRESS_683114] therapy in an important new dopamine receptor -selective 
mechanism for treatment of PD symptoms. By [CONTACT_4122] D1R subtype, tavapadon 
aims to improve motor control symptoms while minimizing adverse  events (AEs) that 
may be mechanistically linked to D2/D3 dopamine receptor agonists (notably, 
dose-limiting hypotension, impulse control disorders, sleep disorders, and, potentially, 
some forms of hallucinations). This trial is designed to further define and confirm the 
magnitude of efficacy and the risk/benefit profile of tavapadon over the target dose range 
of 5 to 15  mg once daily (QD).  
Objectives and Endpoints:  
The objectives and efficacy, safety, and pharmacokinetic (PK) endpoints of the trial are 
summarized in Table  1. 
  
Protocol CVL -751-PD-003 
Tavapadon  
 
Confidential  Page 9 of 90 Version  4.0: 06 Jul 2023      
Table  1 Objectives and Endpoints  
Objectives  Endpoints  
Efficacy   
Primary   
• To assess the effect of tavapadon on the 
change from baseline in total daily 
hours of “on” time without troublesome 
dyskinesia in L -Dopa -treated subjects 
with PD who are experiencing motor 
fluctuations  Primary Efficacy Endpoint  
• Change from baseline to endpoint the total “on” time  
without troublesome dyskinesia based on the 2 -day 
average of the self -completed home diary for motor 
functional status (Hauser diary)  
Secondary    
• To assess the effect of tavapadon on the 
change from baseline in total daily 
hours of “off” time in L -Dopa treated 
subjects with PD who are experiencing 
motor fluctuations  Key Secondary Efficacy Endpoint  
• Change from baseline to endpoint in total daily “off” 
time based on the 2 -day average of the 
self-completed home diary for motor function status 
(Hauser diary)  
Secondary Efficacy Endpoints (at all time points)  
• Change from baseline in the total “on” time without 
troublesome dyskinesia based on the 2 -day average 
of the self -completed home diary for motor function 
status (Hauser diary)  
• Change from baseline in  the total “off” time without 
troublesome dyskinesia based on the 2 -day average 
of the self -completed home diary for motor function 
status (Hauser diary)  
 • Change from baseline in the MDS -UPDRS Part  I 
score  
 • Change from baseline in the MDS -UPDRS Part  II 
score  
 • Change from baseline in the MDS -UPDRS Part  III 
score  
 Other Endpoints  
• Change from baseline in the PDQ -39 score  
• Change from baseline in the EQ -5D-5L index and 
VAS scores  
Safety and Tolerability   
• To assess the safety and tolerability of 
tavapadon in L-Dopa -treated subjects 
with PD who are experiencing motor 
fluctuations  • QUIP -RS 
• ESS 
• C-SSRS  
• Nature, frequency, and temporality of TEAEs, 
including abuse -related AEs and AEs related to 
MHIs  
 • Clinical laboratory evaluations  
 • Vital signs  
• Physical examinations  
• ECGs  
  
Protocol CVL -751-PD-003 
Tavapadon  
 
Confidential  Page 10 of 90 Version  4.0: 06 Jul 2023      
Table  1 Objectives and Endpoints  
Objectives  Endpoints  
Pharmacokinetic   
• To evaluate the PK of tavapadon in 
this population  Plasma concentrations of tavapadon and its metabolite (if 
required) at baseline (Day  1) and at Weeks  5, 11, 14, 22, 
and 27  
Abbreviations: AE  = adverse event, C -SSRS  = Columbia -Suicide Severity Rating Scale, ECG  = electrocardiogram, 
EQ-5D-5L = EuroQol 5 Dimension 5 Level, ESS  = Epworth Sleepi[INVESTIGATOR_7110], L -Dopa  = levodopa, 
MDS -UPDRS  = Movement Disorder Society -Unified Parkinson’s Disease Rating Scale, MHIs  = medica tion handling 
irregularities, PD  = Parkinson’s disease, PDQ -39 = 39-Item Parkinson’s Disease Rating Scale, PK  = pharmacokinetic, 
QUIP -RS = Questionnaire for Impulsive -Compulsive Disorders in Parkinson’s Disease -Rating Scale, 
TEAE  = treatment -emergent adver se event, VAS  = visual analog scale.  
Overall Design:  This is a prospective, Phase  3, multicenter, multinational, randomized, 
double -blind, placebo -controlled, parallel -group, 27 -week trial to evaluate the efficacy, 
safety, tolerability, and PK of tavapadon  as adjunctive therapy to levodopa (L -Dopa) in 
male and female subjects aged [ADDRESS_683115] a diagnosis of PD (consistent 
with the [LOCATION_006] Parkinson’s Disease Society Brain Bank diagnostic criteria); a modified 
Hoehn and Yahr score of 2, 2.5, or 3 in t he “on” state; a minimum of 2½ hours of “off” 
time on 2  consecutive days; and a good response to L -Dopa in the judgment of the 
investigator. The trial will include a Screening Period (maximum of 4  weeks), a [ADDRESS_683116] will participate in the trial for up to approximately 35 weeks, including 
screening (up to 4  weeks), treatment (27  weeks), and posttreatment safety follow up 
(4 weeks). Subjects who complete through Week  27 of the trial may hav e the opportunity 
to enter an open -label extension trial (Protocol  CVL -751-PD-004).  
Disclosure Statement:  This is a parallel -group trial to evaluate the efficacy, safety, 
tolerability, and PK of flexible doses of tavapadon and placebo in subjects with adv anced 
PD. Treatment assignments will be blinded to the investigators and other trial site 
personnel, the subjects, and all sponsor personnel who are involved in the conduct of the 
trial (including trial monitoring, data management, and data analysis).  
Numb er of Subjects: A total of 368 subjects are planned to be randomized into 
2 treatment groups (184 subjects per treatment group).  
Key Entry Criteria:  Male and female subjects aged [ADDRESS_683117] a diagnosis 
of PD (consistent with the [LOCATION_006] Parkinson’s  Disease Society Brain Bank diagnostic 
criteria), a modified Hoehn and Yahr score of 2, 2.5, or 3 in the “on” state, a minimum of 
2½ hours of “off” time on 2 consecutive days, and a good response to L -Dopa in the 
judgment of the investigator will be enroll ed. 
Intervention Groups, Trial Treatments, and Duration: S ubjects will be randomized in 
a 1:1 ratio to receive tavapadon 5 to 15  mg QD or placebo QD. The planned duration of 
treatment is 27  weeks, including the Dose Titration, Dose Adjustment, and Maintena nce 
Phases. The IMPs will be taken orally.  
  
Protocol CVL -751-PD-003 
Tavapadon  
 
Confidential  Page 11 of 90 Version  4.0: 06 Jul 2023      
Interim Analysis Review Committee: Given that the assumptions for the sample size 
were based on a preliminary study using a different dosing schedule, it is unknown if 
these assumptions are appropriate for this st udy as designed. To this end, an interim 
analysis of the primary efficacy endpoint will be included to assess the adequacy of the 
overall sample size relative to achieving the study objectives. This analysis will be 
conducted by [CONTACT_526406] (IARC), which may 
make a recommendation to increase the overall sample size up to a maximum of 
528 subjects. Full details and rules for the IARC and planned interim analysis will be 
provided in a separate IARC charter and in the stati stical analysis plan.  
Statistical Methods  
Sample Size Estimation : A sample size of 184 subjects per group (total, 368 subjects) 
will provide at least 90% power to detect a change in the primary outcome measure 
(change from baseline in “on” time without tro ublesome dyskinesia) of [ADDRESS_683118] deviation of 2.5, a 2 -sided alpha level = 0.049, and assuming a 27% dropout 
rate. 
In the event of higher than anticipated early terminations due to COVID -19 or other 
reasons, Cerevel may extend enrollment in o rder to maintain the planned statistical 
power.  
Efficacy Analyses : The analysis of the primary and each secondary endpoint will include 
the comparison of tavapadon versus placebo. The hypothesis testing will be done in 
hierarchical order from the primary e ndpoint onward. To control for any potential 
inflation of Type I error that may be incurred from the interim analysis, the primary 
hypothesis will be tested at an α level of 0.049 (2 -sided) to ensure that the overall Type I 
error rate is below 0.05. Subseq uent testing in the secondary endpoints will be conducted 
at an α level of 0.05 (2 -sided).  
The primary endpoint (change from baseline to endpoint in “on” time without 
troublesome dyskinesia) will be analyzed using a Mixed Model for Repeated Measures 
(MMRM)  on the modified intent -to-treat (mITT) population. This estimand will be based 
on the [ADDRESS_683119] intercurrent events treated as censored. 
The baseline value will be included as a covariate, and the treatment group (tavapadon or 
placebo), visit, and interaction between treatment group and visit will be included as 
fixed factors in the MMRM. The difference between tavapadon versus placebo at 
endpoint will be estimated based on the least square means (LSMeans) from the MMRM.  
The key secondary endpoint (change from baseline to endpoint in “off” time) and  other 
continuous secondary endpoints (as listed in Table  1) will be analyzed in a similar 
manner to the primary endpoint. Categorical endpoints will be an alyzed on the mITT 
population using the SAS® GLIMMIX procedure for binomial data with logit link. This 
generalized linear mixed model analysis will include response data from each 
 
Protocol CVL -751-PD-003 
Tavapadon  
 
Confidential  Page 13 of 90 Version 4.0: 06 Jul 2023        
Table  2 Schedule of Assessments  
Trial Period:  Screen  Baseline  Treatment  Safety  
Follow -upa 
Trial Week:  -4 to -1 1 2 5 8 11 14 18 22 26 27b 31 
Trial Day:  -31 to -1 1 14±3  35±3  56±3  77±3  98±3  126±3  154±3  182±3  189±3  217±3  
Visit/Contact:  [CONTACT_4838] 1  Visit 2  Visit 3  Visit 4  Visit 5  Visit 6  Visit 7  Visit 8  Visit 9  Visit 10  Visit 11 
(EOT/ET)  Telephonec 
Entrance and History  
Informed consentd X            
Eligibility criteria  X X           
Demography  X            
Psychiatric historye ----------------- →           
Medical historye ----------------- →           
Alcohol/illicit drug use inquiry  X            
Modified Hoehn and Yahr stage  X      X   X X  
MoCA  X            
Randomization   X           
Efficacy and Other Endpoint Assessments  
Hauser diary training video and 
on/off time concordance testingf X            
Dispense Hauser diaryg X X X X X X X X X X X  
Collect/review Hauser diaryg  X X X X X X X X X X  
MDS -UPDRSh X X  X X X X X X X X  
PDQ -39  X        X X  
EQ-5D-5L  X     X   X X  
Safety Assessments  
ESS  X X X X X X X X X X  
QUIP -RS  X X X X X X X X X X  
 
Protocol CVL -751-PD-003 
Tavapadon  
 
Confidential  Page 14 of 90 Version 4.0: 06 Jul 2023        
Table  2 Schedule of Assessments  
Trial Period:  Screen  Baseline  Treatment  Safety  
Follow -upa 
Trial Week:  -4 to -1 1 2 5 8 11 14 18 22 26 27b 31 
Trial Day:  -31 to -1 1 14±3  35±3  56±3  77±3  98±3  126±3  154±3  182±3  189±3  217±3  
Visit/Contact:  [CONTACT_4838] 1  Visit 2  Visit 3  Visit 4  Visit 5  Visit 6  Visit 7  Visit 8  Visit 9  Visit 10  Visit 11 
(EOT/ET)  Telephonec 
C-SSRSi X X X X X X X X X X X  
Physical/neurological examinationj  X          X  
Weight  X X         X  
Vital signsk X X X X X X X X X X X  
Single [ADDRESS_683120] dose of IMPm  X           
      Xw     Xx  
Prior/concomitant medications  -------------------------------------------------------------- --------------------------- ---------------------------------------------------------------------------------------- → 
Adverse eventsn  ------------------------------------------------ --------------------------- ---------------------------------------------------------------------------------------- → 
Laboratoryo 
Safety laboratory blood sample  X X    X   X  X  
Prolactin level   Xv         Xv  
Serology (HIV, HbsAg, and HCV)  X            
Dipstick urinalysisp X X    X   X  X  
Serum pregnancy testq X            
Urine dipstick pregnancy testq  ----------------------------------------------------------------------------------------------------------------------------- --------→  
Urine drug screenr X ------------------------------------------------------------------------------------------------------------------ → X  
Plasma PK samples  X  X  X X  X  X  
Future biospecimen research blood 
samplet  X           

 
Protocol CVL -751-PD-003 
Tavapadon  
 
Confidential  Page 15 of 90 Version 4.0: 06 Jul 2023        
Table  2 Schedule of Assessments  
Trial Period:  Screen  Baseline  Treatment  Safety  
Follow -upa 
Trial Week:  -4 to -1 1 2 5 8 11 14 18 22 26 27b 31 
Trial Day:  -31 to -1 1 14±3  35±3  56±3  77±3  98±3  126±3  154±3  182±3  189±3  217±3  
Visit/Contact:  [CONTACT_4838] 1  Visit 2  Visit 3  Visit 4  Visit 5  Visit 6  Visit 7  Visit 8  Visit 9  Visit 10  Visit 11 
(EOT/ET)  Telephonec 
IMP Administration and Complianceu 
Dispense IMP   X X X X X X X X X   
Assess IMP compliance    X X X X X X X X X  
Abbreviations: C -SSRS  = Columbia -Suicide Severity Rating Scale, ECG  = electrocardiogram, eCRF  = electronic case report form, EQ-5D-5L = EuroQol 5 Dimension 5 Level, 
ESS = Epworth Sleepi[INVESTIGATOR_7110], EOT  = end of treatment, ET  = early termination, HbsAg  = hepatitis B surface antigen, HCV  = hepatitis C virus, HIV  = human immunodeficiency 
virus, IMP  = investigational medicinal product, L-Dopa = levodopa, MDS -UPDRS  = Movement Disorder Society – Unified Parkinson’s Disease 
Rating Scale, MoCA  = Montreal Cognitive Assess ment, PDQ -39 = 39-Item Parkinson’s Disease Questionnaire, PK  = pharmacokinetic, QUIP -RS = Questionnaire for Impulsive -
Compulsive Disorders in Parkinson’s Disease -Rating Scale.  
a. Subjects who prematurely discontinue from the trial or who are not eligible for or choose not to participate in the open -label extension trial (Protocol CVL -751-PD-004) are to 
participate in the [ADDRESS_683121] be obtained before any trial -related procedures are performed.  
e. Medical occurrences that begin before the start of IMP dosing but after obtaining informed consent will be recorded as medica l and/or psychiatric history.  
f. Subjects and  investigators (or qualified designees) will independently complete concordance testing. Full details and requirements for the  conduct and successful completion 
of concordance testing are provided in the appropriate protocol -specific manual.  
g. Subjects will record entries for [ADDRESS_683122] dose of L -Dopa on that day.  
i. The “Baseline/Screening” C -SSRS form will be completed at the Screening Visit to determine eligibili ty. The “Since Last Visit” C -SSRS form will be completed at the 
Baseline Visit to ensure that the subject continues to qualify for the trial and at all visits after the Baseline Visit.  
j. Full physical and neurological examinations should be completed at the Screening Visit and at Week  27. The physical examination should include height at the Screening 
Visit only. Physical and/or neurological examinations can be done at any time point during the trial at the investigator's di scretion.  
k. Duplicate measurements o f blood pressure and heart rate will be obtained supi[INVESTIGATOR_050] (after [ADDRESS_683123]) and 1 measurement of blood pressure and heart rate will be obtained 
on standing (2  minutes after rising from supi[INVESTIGATOR_144658]).  
l. The postdose ECG will be obtained at ~[ADDRESS_683124] prior to the time of collection of the PK blood sample.  
m. A triplicate set  of ECGs is 3 consecutive ECGs collected 1 to 2  minutes apart over a 5 -minute period.  

Protocol CVL -751-PD-003 
Tavapadon  
Confidential  Page 17 of 90 Version  4.0: 06 Jul 2023    
2 INTRODUCTION  
2.1 Trial Rationale  
Tavapadon (PF -06649751, CVL -751) is a partial agonist of the dopamine D1 -like 
receptors (D1Rs), with high specificity for the D1 and D5 receptor subtypes (D1/D5) , 
which is being developed as a treatment for Parkinson's disease (PD). Efforts to develop 
selective D1R agonists have been ongoing for decades, in part, because of their clear 
potential to produce robust efficacy through selective stimulation of the direc t pathway. 
Mechanistic evidence also suggests that selective and partial activation of D1Rs may 
avoid some of the limiting side effects of the D2/[ADDRESS_683125] therapy in an important new dopamine 
receptor -selective mechanism for treatment of PD symptoms. By [CONTACT_4122] D1R 
subtype, tavapadon aims to improve motor control symptoms while minimizing a dverse 
events (AEs) that may be mechanistically linked to D2/D3 dopamine receptor agonists 
(notably, dose -limiting hypotension, impulse control disorders, sleep disorders, and, 
potentially, some forms of hallucinations).  
This prospective, Phase  3, multicen ter, multinational, randomized, double -blind, 
placebo -controlled, parallel -group, 27 -week trial will evaluate the efficacy, safety, 
tolerability, and pharmacokinetics (PK) of flexible doses of tavapadon (5  mg to 15  mg 
once daily [QD]) as adjunctive therapy  for PD in levodopa (L -Dopa) -treated adults with 
motor fluctuations to further define and confirm the magnitude of efficacy and 
risk/benefit profile of this target dose range.  
2.2 Background  
Parkinson’s disease is a chronic, progressive and disabling neurodege nerative disease. 
The number of individuals with PD aged [ADDRESS_683126] populous nations in the world* combined and is projected to double 
to betw een 8.7 and 9.3  million by 2030 ( Dorsey et al, 2007 ). The incidence is 
approximately 20 per 100,000 persons per year, increases with advancing age (65  years 
and older) to up to >100 per 100,000 ( Twelves et al, 2003 ), and is reported to be 1.4% at 
age 55  years and 4.3% at 85  years and older ( de Rijk et al, 1995 ). 
The specific etiology of PD remains unclear, but there are continued advances in 
understanding the possible  underlying mechanisms and causative factors. A more 
complete understanding of basal ganglia function, the neuropathologic and 
neurochemical abnormalities in PD, and genetic forms of parkinsonism provide hope that 
disease -modifying therapeutic approaches c an be identified. However, there remains 
significant current and future need for improved symptomatic therapi[INVESTIGATOR_014].  
*China, India, [LOCATION_002], Indonesia, Brazil, Pakistan, Bangladesh, Russia, Nigeria, and Japan.
  
Protocol CVL -751-PD-003 
Tavapadon  
 
Confidential  Page 18 of 90 Version  4.0: [ADDRESS_683127] localization and primary signaling 
cascades and are commonly divided into 2 groups based on their function. The D1 -like 
family includes the D1 and D5 subtypes, which are localized on a “direct” striatal motor 
control pathway and which stimulate cellular activity by [CONTACT_330198] (cAMP) levels. The D2 -like family includes the D2, D3, and 
D4 subtypes, which are localized to  an “indirect” motor control pathway and which 
decrease intracellular cAMP when activated. The degenerative character of the disease is 
accompanied by [CONTACT_330199] -activation. Basic 
research currently suggests that  oxidative injury to specific neurons in the basal ganglia 
may be at least one of the underlying causes of “idiopathic parkinsonism,” apart from 
other factors, such as genetic changes.  
The major clinical diagnostic features of PD include tremor, rigidity o f skeletal muscles, 
bradykinesia, impairment of postural reflexes (also referred to as parkinsonism), and gait 
disturbances. Additional symptoms include many other motor features and nonmotor 
features, including psychiatric, sensory, and autonomic changes.  Patients may or may not 
require therapy in the early stages of PD, which typi[INVESTIGATOR_526400], and may still be able to work. Unfortunately, disease progression is 
inevitable and, within [ADDRESS_683128] the workforce within 5  years of diagnosis 
(Jasinska -Myga et al, 2012 ). No proven disease -modifying treatments for PD are 
currently available. Management options for PD consist mainly of dopaminergic drugs 
and, in a limited number of patients, deep brain stimulation.  
L-Dopa (the metabolic precursor of dopamine) therapy provides increased dopamine 
levels in a transient and pulsatile fashion and affords rapid improvement of motor 
symptoms. However, prolonged use of L -Dopa leads to the development of motor 
complications in most patients. These include m otor fluctuations, which are an 
alternation between “on” periods when motor symptoms are well controlled and “off” 
periods when motor symptoms are poorly controlled. An additional type of motor 
complication is the occurrence of dyskinesia or abnormal invol untary movements 
(Marconi et al, 1994 ; Vijayakumar and Jankovic, 2016 ). Troublesome motor 
complications from L -Dopa therapy can lead to substantial impairment, negative impacts 
on activities  of daily living, and decreased quality of life.  
Agents that preferentially activate the dopamine D2 and D3 receptor subtypes (D2/D3R), 
such as pramipexole, ropi[INVESTIGATOR_11122], and rotigotine, are also approved for the symptomatic 
  
Protocol CVL -751-PD-003 
Tavapadon  
 
Confidential  Page 19 of 90 Version  4.0: 06 Jul 2023    
treatment of PD ( Stocchi et al, 2016 ). These  agents generally exhibit less frequent motor 
complications than L -Dopa but are not as effective for controlling motor symptoms 
(Connolly  and Lang, 2014 ; Rizek et al, 2016 ; Dietrichs and Odin, 2017 ). 
D2/D3 -preferring agonists are also associated with an increased incidence of specific 
adverse effects, including somnolence, hypotension, compulsive behaviors, and 
hallucination s, particularly in the elderly ( Stowe  et al, 2008 ). 
Selegiline, rasagiline, and safinamide  are monoamine oxidase B (MAO -B) inhibitors, 
which block one pathway of dopamine degradation and improve motor symptoms of PD 
in some set tings ( Connolly and Lang, 2014 ; Binde et al,  2018 ). Of these, only rasagiline 
is approved in the [LOCATION_002] and Europe as a monotherapy treatment, and available 
indirect evidence suggests that  this class is less efficacious than D2/3 agonists (Stowe et 
al, 2008 ; Zhuo et al, 2017 ). 
Despi[INVESTIGATOR_330176], the chronic and progressive nature of PD 
continues to result in significant burden and impact on quality of life and day -to-day 
functioning for patients ( Drutyte et al, 2014 ). There are significant unmet medical needs 
throughout the stages of PD, from improving motor control in patients w ith early -stage 
disease who have not yet begun dopamine replacement therapy, to increasing daily “on” 
time without troublesome dyskinesias while adequately controlling motor symptoms in 
patients with moderate -to-advanced disease who are receiving available  therapi[INVESTIGATOR_014] 
(patients with motor fluctuations). Patients and their families are anxious for testing of 
new therapeutic mechanisms that can provide strong and lasting control of the symptoms 
of PD and that can minimize some of the known side effects of exist ing therapeutic 
options, such as dose -limiting dyskinesias, daytime sleepi[INVESTIGATOR_008], and impulsivity. 
Completed Phase  1b and [ADDRESS_683129] demonstrated that tavapadon can provide improved 
control of motor symptoms in both early and more advanced stages of PD, w ith an 
acceptable safety profile.  
2.3 Benefit/Risk Assessment  
In a Phase  1b trial in subjects with PD with motor fluctuations (Trial  B7601009), 
increasing benefit on motor symptoms was observed with increased tavapadon dose, with 
magnitudes of change on the Mo vement Disorder Society  – Unified Parkinson’s Disease 
Rating Scale (MDS -UPDRS) Part  III scores well above the changes that are recognized 
as clinically meaningful (>3 -point decrease from baseline; Horváth et al, 2015 ) and 
signif icantly better than for placebo. Sustained effects of tavapadon on tremor (as shown 
by [CONTACT_292795] -UPDRS Part  III scores that were lower than at baseline for up to 12  hours 
after dosing) were also observed in a second Phase  1b trial in subjects with PD with 
motor fluctuations (Trial  B7601005).  
In a Phase  2 trial of tavapadon in L -Dopa -treated subjects with PD who were 
experiencing motor fluctuations (Trial  B7601003), analysis of the change from baseline 
in average daily “on” time without troublesome dyskinesia showed that the magnitude of 
benefit of tavapadon 15  mg QD, relative to placebo, was approximately 1  hour at 
Week  10. Although the difference from placebo did not achieve statistical significance 
  
Protocol CVL -751-PD-003 
Tavapadon  
 
Confidential  Page 20 of 90 Version  4.0: 06 Jul 2023    
due to the small sample size, this difference is considered clinically meaningful ( Hauser 
et al, 2011 ; Hauser et al, 2014 ).  
Motor symptoms were significantly more improved with tavapadon monotherapy than 
with placebo in a Phase  2, placebo -controlled, 15 -week, flexible -dose trial in subjects 
with early PD (Trial  B7601011), as assessed by [CONTACT_63202]  15 in 
the MDS -UPDRS Part  III total score (least square mean [LSMean] change from 
baseline  = -9.0 for tavapadon and -4.3 for placebo; differ ence from placebo  = -4.8; 
p=0.041). The difference between tavapadon and placebo in the change from baseline to 
Week  15 in the MDS -UPDRS Parts  II and III combined score was also statistically 
significant (LSMean change from baseline  = -11.2 for tavapadon a nd -5.4 for placebo; 
difference from placebo: -5.9; p=0.020). The magnitude of the placebo -adjusted 
treatment difference in improvement from baseline in the MDS -UPDRS Part III score 
met the threshold for a clinically meaningful change (>3 -point decrease fr om baseline; 
Horváth et al, 2015 ), as did the magnitude of the placebo -adjusted treatment difference in 
improvement from baseline in the MDS -UPDRS Parts II and III combined score 
(>4.9 -point decrease from baseline; Makkos et al, 2018 ). 
The safety results across all clinical trials demonstrate that tavapadon was generally 
well tolerated up to a titrated dose of 15  mg QD in subjects with PD, either as 
monotherapy (early PD) or as adjunctive treatmen t with a stable dose of L -Dopa 
(advanced PD). A dose -dependent increase in the frequencies of nausea and headache 
was observed across all trials. Nausea, vomiting, dyskinesia, fall, fatigue, sleep disorder, 
and tremors were the most common AEs leading to d iscontinuation of tavapadon. The 
appearance of nausea, orthostatic blood pressure changes, and fatigue is often related to 
the speed of titration with dopamine receptor agonists (historically with D2 agents) and 
may be mitigated by a slower titration metho d. 
No notable differences in laboratory abnormalities, electrocardiogram (ECG) parameters, 
or suicidality assessments were observed between tavapadon and placebo. Multidose 
cohorts in Phase  1 trials in healthy volunteers and subjects with PD (including sub jects 
with PD who were treated at doses of up to 25  mg QD of tavapadon) did not suggest that 
tavapadon prolonged the QT interval corrected for heart rate by [CONTACT_6550]’s formula 
(QTcF). Trials of longer treatment duration suggest a tavapadon dose -related d ecrease 
from baseline in systolic and/or diastolic parameters, with some cases of asymptomatic 
hypotension. This finding is common with dopamine D2 agonists and is prevalent in the 
population of patients with PD whether treatment naïve or treated with L -Dopa. 
Taken together, the current data suggest an appropriate benefit -risk ratio for further 
evaluation of tavapadon in Phase  3 clinical trials at doses up to 15  mg QD. Additional 
information about the known and expected benefits, risks, and AEs of tavapadon  is 
provided in the Investigator’s Brochure.  
In response to the COVID -19 pandemic, Cerevel has performed a risk assessment of this 
trial and the investigator of each individual trial site and has implemented measures 
throughout the protocol, which prioriti zes trial participant safety and data validity.  
  
Protocol CVL -751-PD-003 
Tavapadon  
 
Confidential  Page 21 of 90 Version  4.0: 06 Jul 2023    
3 OBJECTIVES AND ENDPO INTS  
The trial objectives and endpoints are summarized in Table  3. 
Table  3 Objectives and Endpoints  
Objectives  Endpoints  
Efficacy   
Primary   
• To assess the effect of tavapadon on the 
change from baseline in total daily 
hours of “on” time without troublesome 
dyskinesia in L -Dopa -treated subjects 
with PD who are experiencing motor 
fluctuations  Primary Efficacy Endpoint  
• Change from baseline to endpoint the total “on” time 
without troublesome dyskinesia based on the 2 -day 
average of the self -completed home diary for motor 
function status (Hauser diary)  
Secondary    
• To assess the effect of tavapadon on the 
change from baseline in total daily 
hours of “off” time in L -Dopa treated 
subjects with PD who are experiencing 
motor fluctuations  Key Secondary Efficacy Endpoint  
• Change from baseline to endpoint in total daily “off” 
time based on the 2 -day average of the 
self-completed home diary for motor function status 
(Hauser diary)  
Secondary Efficacy Endpoints (at all time points)  
• Change from baseline in the total “on” time without 
troublesome dyskinesia based on the 2 -day average 
of the self -completed home diary for motor function 
status (Hauser diary)  
• Change from baseline in the total “off” time without 
troublesome dyskinesia based on the 2 -day average 
of the self -completed home diary for motor function 
status (Hauser diary)  
 • Change from baseline in the MDS -UPDRS Part  I 
score  
 • Change from baseline in the MDS -UPDRS Part  II 
score  
 • Change from baseline in the MDS -UPDRS Part  III 
score  
 Other Endpoints  
• Change from baseline in the PDQ -39 score  
• Change from baseline in the EQ -5D-5L index and 
VAS scores  
Safety and Tolerability   
• To assess the safety and tolerability of 
tavapadon in L -Dopa -treated subjects 
with PD who are experiencing motor 
fluctuations  • QUIP -RS 
• ESS 
• C-SSRS  
• Nature, frequency, and temporality of TEAEs, 
including abuse -related AEs and AEs related to 
MHIs  
 • Clinical laboratory evaluations  
 • Vital signs  
• Physical examinations  
• ECGs  
  
Protocol CVL -751-PD-003 
Tavapadon  
 
Confidential  Page 22 of 90 Version  4.0: 06 Jul 2023    
Table  3 Objectives and Endpoints  
Objectives  Endpoints  
Pharmacokinetic   
• To evaluate the PK of tavapadon in 
this population  Plasma concentrations of tavapadon and its metabolite (if 
required) at baseline (Day  1) and at Weeks  5, 11, 14, 22, 
and 27  
Abbreviations: AE  = adverse event, C -SSRS  = Columbia -Suicide Severity Rating Scale, ECG  = electrocardiogram, 
EQ-5D-5L = EuroQol 5 Dimension 5 Level, ESS  = Epworth Sleepi[INVESTIGATOR_7110], L -Dopa  = levodopa, 
MDS -UPDRS  = Movement Disorder Society -Unified Parkinson’s Disease Rating Scale, MHIs  = medication handling 
irregularities, PD  = Parkinson’s disease, PDQ -39 = 39-Item Parkinson’s Disease Rating Scale, PK  = pharmacokinetic, 
QUIP -RS = Questionnaire for Impulsive -Compulsive Disorders in Parkinson’s Disease -Rating Scale, 
TEAEs  = treatment -emergent adverse events, VAS  = visual analog scale.  
4 TRIAL DE SIGN  
4.1 Overall Design  
This is a prospective, Phase  3, multicenter, multinational, randomized, double -blind, 
placebo -controlled, parallel -group, 27 -week trial to evaluate the efficacy, safety, 
tolerability, and PK of tavapadon as adjunctive therapy to levodop a (L-Dopa) in male and 
female subjects aged [ADDRESS_683130] a diagnosis of PD (consistent with the [LOCATION_006] 
Parkinson’s Disease Society Brain Bank diagnostic criteria); a modified Hoehn and Yahr 
score of 2, 2.5, or 3 in the “on” state; a minimum of 2½ ho urs of “off” time on 
2 consecutive days; and a good response to L -Dopa in the judgment of the investigator. 
The trial will include a Screening Period (maximum of 4  weeks), a 27 -week Treatment 
Period, and a 4 -week Safety Follow -up Period ( Figure  1). Each subject will participate in 
the trial for up to approximately 35  weeks.  
4.1.1  Screening/Baseline Period  
Subjects who provide written informed consent will be scr eened for eligibility during the 
Screening Period. During the Screening Period, subjects will be trained in the use of the 
home diary (Hauser diary), and subjects and investigators (or qualified designee) will 
independently complete concordance testing on the Hauser diary (full details and 
requirements for conduct and successful completion of concordance testing are provided 
in the appropriated protocol -specific manual). Subjects who successfully meet the 
concordance testing criteria will complete the Hause r diary on at least 2 consecutive days 
(24-hour periods) within the 7  days before the Baseline Visit.  
Subjects whose diary shows a minimum of 2½ hours of “off” time on each of the 2  days 
and who continue to satisfy the trial eligibility criteria at the Bas eline Visit will be 
randomized in a 1:1 ratio to receive:  
  
Protocol CVL -751-PD-003 
Tavapadon  
 
Confidential  Page 23 of 90 Version  4.0: 06 Jul 2023    
• Tavapadon ranging from 5 to 15  mg QD  
• Placebo QD  
4.1.[ADDRESS_683131] 
14 weeks of the trial during the Dose Titration and Dose Adjustment Phases unless 
prevented by [INVESTIGATOR_458904]. A reduction in dose (from 15  mg QD to 10  mg QD or from 
10 mg QD to 5  mg QD) will be allowed based on individual subject tolerability. Subjects 
who require a dose reduction may be rechallenged with the higher dose, at the discretion 
of the investigator, to address symptomatic needs.  
The titration schedule, as s hown in Table  4, will be used for all subjects who are 
randomized to receive tavapadon. Subjects will take 3  tablets of IMP, either all tavapadon 
tablets, all placebo tablets, or a combination of tavapadon and placebo tablets, throughout 
the trial to maintain the trial blind.  
Table  4 Tavapadon and Placebo Dosing Schedule  
Trial Day  Titration Step  Blinded Treatment Assignment  
Maintenance Phasec 
  Maximum tolerated tavapadon dose (5 -15 mg) or placebo QD  
Abbreviation: QD = once daily.  
a. No deviations in the titration schedule up through [ADDRESS_683132] tolerated dose leve l that is achieved during the Dose Adjustment 
Phase. No adjustment in the tavapadon dose will be allowed during the Maintenance Phase.  

  
Protocol CVL -751-PD-003 
Tavapadon  
 
Confidential  Page 24 of 90 Version  4.0: 06 Jul 2023    
No deviations in the titration schedule up through  (5 mg QD) will be allowed. 
Titration of tavapadon should be gui ded by [CONTACT_526407] . Any questions regarding tolerability issues and titration should be directed to 
the medical monitor before adjustments are initiated. The dose of tavapadon will be 
gradually titrated to the  dose (15  mg QD) in all subjects, as shown  Table  4, 
unless prevented by [INVESTIGATOR_458904].  
Subjects who are unable to achieve or tolerate the  dose (15  mg QD) may receive 
the  dose (10  mg QD). Subjects who cannot achieve or tolerate the  dose 
(10 mg QD) may receive the  dose (5  mg QD).  Subjects who cannot achieve or 
tolerate the  dose (5  mg QD) will be discontinued from the trial. Subjects who 
require a dose reduction may be rechallenged with a higher dose to address symptomatic 
needs after at least [ADDRESS_683133] dose of IMP will be taken at the trial site at the Baseline Visit; all other doses 
will be taken on an outpatient basis. Assessment s will be conducted in the clinic at the 
end of Weeks  2, 5, 8, 11, 14, 18, 22, 26, and 27. Subjects will complete the Hauser diary 
on [ADDRESS_683134] dose on Day  1 
(~1 hour after dosing) and at the Weeks  5, 11, 14, 22, and [ADDRESS_683135] the opportunity to enter an 
open -label exten sion trial (Protocol  CVL -751-PD-004). Subjects who are ineligible or 
elect not to enter the open -label trial will be contact[CONTACT_162776] 4  weeks after 
discontinuation of trial treatment (either after completing the full 27 -week treatment 
period or up on premature discontinuation from the trial).  
4.2 Scientific Rationale for Trial Design  
The randomized, double -blind, placebo -controlled, parallel -group trial design is widely 
accepted as one that minimizes the risk of bias and that is appropriate for evaluati ng the 
effects of a trial treatment in indications in which use of a placebo is ethical ( US FDA, 
2001 ). Randomization reduces bias in the assignment of subjects to a treatment group, the 
double -blind design prevents diffe rential treatment and assessments, and the 
placebo -controlled design controls for all potential influences on the actual or apparent 
course of the disease other than those arising from the pharmacologic action of the drug.  
The Hauser diary ( Hauser  et al, 2000 ) assesses patient -defined clinical status over a 
period of time and provides a tool for assessment of the change in “off” time and “on” 

  
Protocol CVL -751-PD-003 
Tavapadon  
 
Confidential  Page 25 of 90 Version  4.0: 06 Jul 2023    
time with troublesome dyskinesia (which is a more accurate reflection of clinical 
response than “off” time alone. The minimum clinically important difference (smallest 
change that is meaningful to patients) for a reduction in “off” time (key secondary 
efficacy endpoint) has been reported to be 1.0  hour ( Hauser et al, 2011 ; Hauser  et al, 
2014 ). 
The MDS -UPDRS is a comprehensive assessment that is designed to monitor the burden 
and extent of PD across the longitudinal disease course and provides a clinical endpoint 
in therapy trials ( Goetz et al, 2008 ).  
The safety endpoints, including physical and neurological examinations, vital signs, 
ECGs, laboratory evaluations, and AEs, are those commonly used to assess the safety and 
tolerability of trial treatments. The Questionnaire for Impulsive -Compulsive Disorders in 
Parkinson’s Disease Rating Scale (QUIP -RS) is a global screening instrument that 
assesses impulsive control disorders (ICDs) and related disorders (punding, hobby[CONTACT_128053], 
and dopamine dysregulation syndro me) in patients with PD ( Weintraub et al, 2012 ), and 
the Epworth Sleepi[INVESTIGATOR_7110] (ESS) is a scale that is intended to measure daytime 
sleepi[INVESTIGATOR_008] ( Johns, 1991 ). The Columbia -Suicide Severity Rating Scale (C -SSRS) is 
commonly used for stringent monitoring of suicidality in clinical trials of neurological 
compounds ( Posner et al, 2011 ).  
4.[ADDRESS_683136] motor control as a ke y attribute of a desirable 
symptomatic therapeutic. In the small, Phase  2, flexible -dose, 15 -week trial of tavapadon 
in early PD (Trial  B7601011), subjects gradually increased their dose of tavapadon at 
weekly intervals, as tolerated, during the initial 9 -week dose optimization period until 
their parkinsonian symptoms were optimally controlled. The target dose range was 3 to 
15 mg QD; however, a maintenance dose of <[ADDRESS_683137] been selected, based on 
clinical response. Of the 26  subjects who were randomi zed to tavapadon and who reached 
the 6 -week maintenance dosing phase, 73% required doses of 5 to 15  mg QD to achieve 
optimized motor control based on clinical judgement. Reduction from baseline in motor 
symptoms of >10 points on the MDS -UPDRS Part  III scor e primarily occurred in 
subjects who received doses of >[ADDRESS_683138] separation from 
placebo treatment achieved at doses >7  mg QD ( -6.9 placebo -adjusted treatment 
difference), whereas a dose of 3  mg QD consistently produced reductions of <[ADDRESS_683139] that doses <[ADDRESS_683140] patients with PD.  
In a Phase  1 multiple -dose trial in su bjects with PD (Trial  B7601005), tavapadon 
exposure increased with an increase in dose over the dose range of 5 to 15  mg; however, 
the increase in mean area under the plasma concentration -time curve over the dosing 
interval (24  hours; AUC tau) and in mean m aximum observed plasma concentration (C max) 
was less than dose proportional between the 15 and 25  mg doses. This is consistent with 
the known moderate -to-low solubility of tavapadon at the pH of the gastrointestinal track 
  
Protocol CVL -751-PD-003 
Tavapadon  
 
Confidential  Page 26 of 90 Version  4.0: 06 Jul 2023    
(pH 6.5), which likely limited abs orption. Therefore, doses >[ADDRESS_683141] that doses >[ADDRESS_683142] an optimal risk/benefit profile for patients with PD.  
Taken together, these findings suggest that an optimal d ose range of tavapadon for the 
treatment of PD may reasonably be between [ADDRESS_683143] visit (including phone contact) of the 
last subject in the trial globally.  
5 TRIAL POPULATION  
Prospective approval of protocol deviations to the recruitment and enrollment criteria, 
also known as protocol waivers or exemptions, is not permitted.  
5.1 Inclusion Criteria  
Subjects are eligible to be include d in the trial only if all of the following criteria apply:  
General and Administrative  
1.  Male and female subjects aged [ADDRESS_683144] agree to use acc eptable (at 
minimum) or highly effective birth control, as defined in Section  10.4 (Appendix  4), or remain 
abstinent during the trial and for [ADDRESS_683145] dose of trial treatment.  
3.  Subjects who are capable of giving signed informed consent as described in Section  10.1.3  
(Appendix  1), which includes compliance with the requirements and restrictions listed in the ICF 
and in this protocol.  
4.  Subjects who are able, in the opi[INVESTIGATOR_871], to understand  the nature of the trial and 
comply with protocol requirements, including the prescribed dosage regimens, scheduled visits, 
laboratory tests, and other trial procedures.  
  
Protocol CVL -751-PD-003 
Tavapadon  
 
Confidential  Page 27 of 90 Version  4.0: 06 Jul 2023    
Parkinson’s Disease Diagnosis  
5.  Subjects with a diagnosis of PD that is consistent with the [LOCATION_006] Parkinson’s Disease Society Brain 
Bank diagnostic criteria.  
Note: Subjects having more than one affected relative (Step 2 [LOCATION_006] Parkinson’s Disease Society 
Brain Bank exclusion criterion) but mee ting all other criteria consistent with the [LOCATION_006] criteria will 
be considered to have met eligibility criteria for a diagnosis of PD ( Litvan et al, 2003 ; Massano 
and Bhatia, 2012 ). 
Note: Motor asymm etry may or may not be present at the time of Screening, and is not an explicit 
requirement for inclusion, as long as the subject meets the [LOCATION_006] Parkinson’s Disease Society Brain 
Bank  diagnostic criteria based on medical history or physical examination.  
6.  Subjects with modified Hoehn and Yahr stage 2, 2.5, or 3 in the “on” state.  
7.  Subjects with a good response to L -Dopa in the judgment of the investigator.  
Note: Subjects using levodopa/carbidopa intestinal gel are not eligible to participate in the trial.  
8.  Subjects who return a completed self -reported home diary for motor function status (Hauser 
diary) during the screening period (after diary training and concordance testing has occurred), 
with recordings for 2  consecutive days (ie, 2 consecutive 24 -hour per iods) showing at least 
2½ hours of “off” time on each of the 2  days.  
Concomitant Parkinson’s Disease Medications  
9.  Subjects who are on a stable dose of L -Dopa for at least [ADDRESS_683146] 
carbidopa/levodopa or divided in at least 3 doses per day of extended -release carbidopa/levodopa 
capsules. The carbidopa/levodopa dose and frequency must be maintained for the duration of the 
trial.  
Standard  or extended -release levodopa/benserazide is allowed as an alternative to 
levodopa/carbidopa, where available. The minimum dose and frequency requirements for 
levodopa still apply.  
10.  Prior and concurrent use of COMT inhibitors, MAO -B inhibitors, amantadine, istradefylline, or 
anticholinergic drugs is permitted if use was initiated >90  days before the Baseline Visit and the 
dosage will remain stable for the duration of the trial (ie, no change in the COMT, MAO -B 
inhibitor, amantadine, istradefyllin e, or anticholinergic dose is permitted during the trial).  
Abbreviations: COMT  = catechol -O-methyl transferase, ICF = informed consent form, IMP  = investigational 
medicinal product, L -Dopa  = levodopa, MAO -B = monoamine oxidase inhibitor B, PD  = Parkinson’ s disease.  
5.2 Exclusion Criteria  
Subjects are excluded from the trial if any of the following criteria apply:  
Parkinson’s Disease Diagnosis  
1.  Subjects with a history or clinical features consistent with essential tremor, atypi[INVESTIGATOR_526401] (including, but not limited to, progressive supranuclear palsy, multiple 
system atrophy, cortico -basal degeneration, or drug -induced or poststroke parkinsonism).  
2.  Subjects with a history of nonresponse or insufficient response to L -Dopa at therapeutic dosages.  
3.  Subjects who have had previous surgical intervention (eg, deep brain stimulation) for PD or for 
whom such a procedure is planned or anticipated during the trial period.  
  
Protocol CVL -751-PD-003 
Tavapadon  
 
Confidential  Page 28 of 90 Version  4.0: [ADDRESS_683147]’s medical 
conditions(s) and the potential impact of the condition(s) on trial participation.  
5.  Subjects with a history or current diagnosis of a clinically significant impulse control disorder 
(Disruptive, Impulse Control, and Conduct Disorder per DSM -5) (American Psychiatric 
Association, 2013 ). 
6.  Subjects with the presence of or history of brain tumor, hospi[INVESTIGATOR_330178], 
epi[INVESTIGATOR_002] (as defined by [CONTACT_330203][INVESTIGATOR_002]), or seizures.  
7.  Subjects with a history of psychosis or hallucinations within the previou s 12 months.  
8.  Subjects who answer “yes” on the C -SSRS Suicidal Ideation Item 4 or Item  5 (Active Suicidal 
Ideation with Some Intent to Act, Without Specific Plan, or Active Suicidal Ideation with 
Specific Plan and Intent) and whose most recent epi[INVESTIGATOR_526402] C -SSRS Item  [ADDRESS_683148] 6 months, OR 
Subjects who answer “yes” on any of the 5 C -SSRS Suicidal Behavior Items (actual attempt, 
interrupted attempt, aborted attempt, preparatory acts, or behavior) and whose mos t recent 
epi[INVESTIGATOR_330180] [ADDRESS_683149] 6  months (180  days).  
10.  Subjects with dementia or cognitive impairment that, in the judgement of the investigator, would 
exclude the subject from understandin g the ICF or participating in the trial.  
11.  Subjects with any condition that could possibly affect drug absorption, including bowel 
resections, bariatric weight loss surgery, or gastrectomy (this does not include gastric banding).  
12.  Subjects who have a positive result for HIV antibodies, HbsAg, or HCV antibodies at screening.  
Note: Subjects who were previously infected with hepatitis C but have been successfully treated 
(defined as a sustained virologic response or undetectable hepatitis C viral RNA leve ls at 12 or 
more weeks after the end of treatment) may be enrolled after discussion with the medical 
monitor.  
  
Protocol CVL -751-PD-003 
Tavapadon  
 
Confidential  Page 29 of 90 Version  4.0: 06 Jul 2023    
13.  Subjects with a history of malignancy other than:  
• Non-metastatic basal or squamous cell carcinoma of the skin or carcinoma in situ that 
was surgically removed in total >1  year before signing the ICF and had not recurred  
• Another type of malignancy that had been in remission for ≥5 years before signing the 
ICF and had not  recurred  
14.  Subjects with a history of myocardial infarction with residual atrial, nodal, or ventricular 
arrhythmias that are not controlled with medical and/or surgical intervention; second - or 
third -degree atrioventricular block; sick sinus syndrome; severe or unstable angina; or congestive 
heart failure within the last 12  mont hs. A recent (≤12  months) history of myocardial infarction 
with secondary arrhythmias is exclusionary regardless of the therapeutic control.  
15.  Subjects with a history of neuroleptic malignant syndrome.  
16.  Female subjects who are breastfeeding and/or who hav e a positive pregnancy test result prior to 
receiving IMP.  
Prior or Concomitant Medications  
17.  Subjects who are currently receiving moderate or strong CYP3A4 inducers or CYP3A4 inhibitors 
(except for topi[INVESTIGATOR_78086]).  
18.  Subjects with a positive urine drug screen for illicit drugs are excluded and may not be retested or 
rescreened. Subjects with a positive urine drug screen resulting from use of marijuana (any 
THC -containing product), prescription, or over -the-counter medications or products that,  in the 
investigator’s documented opi[INVESTIGATOR_1649], do not signal a clinical condition that would impact the safety 
of the subject or interpretation of the trial results may continue evaluation for the trial following 
consultation and approval by [CONTACT_274039] r. 
19.  Subjects who are using prohibited medications prior to randomization (as listed in Table  6) or 
who would be likely to require the use of prohibited  concomitant medications during the trial (as 
listed in Table  7). 
Screening Assessments  
20.  Subjects with a MoCA score <26.  
21.  Subjects with a supi[INVESTIGATOR_9204] ≥160 mmHg (systolic) or ≥100 mmHg (diastolic) at 
screening. The average of two supi[INVESTIGATOR_330181].  
22.  Subjects with clinically significant orthostatic hypotension (eg, syncope).  
23.  Subjects with a 12 -lead EC G demonstrating a QTcF interval >450  msec  
At screening:  
• If the QTcF interval is >[ADDRESS_683150] will  be excluded if the QTcF interval is >450  msec on 2 or 
more of the 3 ECG recordings, unless due to ventricular pacing.  
 At baseline:  
• If the QTcF interval is >[ADDRESS_683151] remains eligible to be randomized while awaiting the 
readings from the central service.  
24.  Subjects with moderate or severe renal impairment (creatinine clearance as estimated by 
[CONTACT_3158] -Gault formula <30  mL/min or on dialysis).  
  
Protocol CVL -751-PD-003 
Tavapadon  
 
Confidential  Page 30 of 90 Version  4.0: 06 Jul 2023    
25.  Subjects with any of the  following abnormalities in clinical laboratory tests at the Screening 
Visit, as assessed by [CONTACT_330204] a single repeat measurement, if 
deemed necessary:  
• AST or ALT ≥3 × ULN.  
• Total bilirubin ≥1.5 × ULN. Subjects with a history of Gilbert's syndrome may be 
eligible provided they have a value <ULN for direct bilirubin.  
26.  Subjects with other abnormal laboratory test results, vital sign results, or ECG findings unless, in 
the judgment of the investigator, the findings are not medically significant and would not impact 
the safety of the subjects or the interpretation of the trial results. The medical monitor should be 
contact[CONTACT_35040], as needed. Tests with exclusionary results should be 
repeated to ensure r eproducibility of the abnormality before excluding a subject based on the 
criteria provided in the protocol. For medically significant or exclusory abnormal ECGs results, [ADDRESS_683152] who, in the opi[INVESTIGATOR_37021], investigator, or medical monitor, should not 
participate in the trial.  
Abbreviations: AE  = adverse event, ALT  = alanine aminotransferase, AST  = aspartate aminotransferase, 
C-SSRS  = Columbia -Suicide Severity Rating Scale, CYP  = cytochrome P450, DSM -5 = Diagnostic and Statistical 
Manual of Mental Disorders, 5th Edition, ECG  = electrocardiogram, HbsAg  = hepatitis B surface ant igen, 
HCV  = hepatitis C virus, HIV  = human immunodeficiency virus, ICF  = informed consent form, IMP  = investigational 
medicinal product, L -Dopa  = levodopa, MoCA  = Montreal Cognitive Assessment, PD  = Parkinson’s disease, 
QTcF  = QT interval as corrected for heart rate by [CONTACT_6550]’s formula, THC  = tetrahydrocannabinol, ULN  = upper 
limit of normal.  
5.3 Lifestyle Considerations  
Subjects should take the IMP at approximately the same time each day (in the morning at 
~24-hour intervals), with or without food. No life style restrictions will be imposed.  
5.4 Screen Failures  
Screen failures are defined as subjects who consent to participate in the clinical trial but 
who are not subsequently randomized to treatment in the clinical trial. A minimal set of 
screen failure informa tion is required to ensure transparent reporting of screen failure 
subjects to meet the Consolidated Standards of Reporting Trials (CONSORT) publishing 
requirements and to respond to queries from regulatory authorities. Minimal information 
includes demogra phy, screen failure details, and eligibility criteria.  
Individuals who do not meet the criteria for participation in this trial (screen failure) at 
screening may be rescreened once at the discretion of the investigator and after 
consultation with the spons or unless screen failure is due to a positive urine drug screen 
for illicit substances other than tetrahydrocannabinol (THC) ( Section  5.2). Subjects w ho 
  
Protocol CVL -751-PD-003 
Tavapadon  
 
Confidential  Page 31 of 90 Version  4.0: [ADDRESS_683153] number.  
6 TRIAL TREATMENTS  
Trial treatment is defined as any investigational treatment(s), marketed product(s), 
placebo, or medical device(s) that is intended to be administered to a trial subject 
according to the trial protocol. Investigational medicinal product (IMP) refers to a 
pharmaceutical form of any active substance or placebo that is being tested in this clinical 
trial. 
6.1 Trial Intervention(s) Administered  
Tavapadon or matching placebo will be administered or ally once daily for up to 27  weeks 
(Table  5). 
Table  5 Investigational Medicinal Products Administered  
ARM Name  [CONTACT_330238] 5 -15 mg QD  Placebo QD  
Type  Drug  Matching drug  
Dose Formulation  Tablet  Matching tablet  
Unit Dose Strength(s)   0 mg 
Dosage Level(s)  5 mg 0 mg 
Route of Administration  Oral Oral 
Sourcing  Cerevel Therapeutics  Cerevel Therapeutics  
Packaging and Labeling  Blister cards labeled according 
to local regulations  Blister cards labeled according 
to local regulations  
Former Name(s)  PF-06649751, CVL -751 -- 
6.2 Preparation/Handling/Storage/Accountability  
The investigator or designee must confirm appropriate temperature conditions have been 
maintained during transit (original shipment and/or moving of IMP supply from one 
office or facility to another within the sites network) for all IMP received and any 
discrepancies are reported and resolved before use of th e IMP.  
Only subjects who are enrolled in the trial may receive IMP and only authorized site staff 
may supply or administer IMP. All IMP must be stored in a secure, environmentally 
controlled, and monitored (manual or automated) area in accordance with the labeled 
storage conditions, with access limited to the investigator and authorized site staff.  
The investigator is responsible for IMP accountability, reconciliation, and record 
maintenance (ie, receipt, reconciliation, and final disposition records).  

  
Protocol CVL -751-PD-003 
Tavapadon  
 
Confidential  Page 32 of 90 Version  4.0: 06 Jul 2023    
Further guidance and information for the final disposition of unused IMPs are provided in 
the appropriate protocol -specific manuals.  
6.3 Measures to Minimize Bias: Randomization and Blinding  
6.3.[ADDRESS_683154] Assignment to Treatment  
All subjects will be centrally randomized  in a 1:1 ratio to 2  treatment arms (tavapadon 
5 to 15  mg QD or placebo) at the Baseline Visit via an Interactive Voice Response 
System/Interactive Web Response System (IVRS/IWRS), according to a 
computer -generated randomization scheme. Subjects will be se quentially assigned to the 
next available randomization number and will receive the IMP that corresponds to that 
randomization number. Once a randomization number has been assigned, it will not be 
reassigned.  
The telephone number and call -in directions for  the IVRS and/or the log -in information 
for and directions for the IWRS will be provided to each trial site before the trial is 
initiated.  
6.3.2  Blinding  
The tavapadon and placebo tablets will be identical in appearance and will be packaged 
in identically appearing blister cards. All subjects will take 3  tablets once daily of IMP 
during the Treatment Period, either all tavapadon tablets, all placebo tablets , or a 
combination of tavapadon and placebo tablets. Tablets will be packaged to allow dosage 
adjustments (as shown in Table  4) to be made without breaking the trial blind.  
Treatment assignments will be blinded to the investigators and other trial site personnel, 
the subjects, and all sponsor personnel who are involved in the conduct of the trial 
(including trial monitoring, data management, and data  analysis). Access to the treatment 
codes will be restricted to personnel who are responsible for generating and maintaining 
the randomization code, packaging the IMPs, operating the IVRS/IWRS, analyzing the 
PK blood samples, or reporting serious adverse e vents (SAEs) or adverse events of 
special interest (AESI) to regulatory agencies.  
At the initiation of the trial, investigators and site personnel will be instructed on the 
method for breaking the blind. The IVRS/IWRS will be programmed with blind -breaking  
instructions. In case of an emergency, the investigator has the sole responsibility for 
determining if unblinding of the treatment assignment for an individual subject is 
warranted. Subject safety must always be the first consideration in making such a 
determination. If the investigator decides that unblinding is warranted, the investigator 
should make every effort to contact [CONTACT_330206] a subject’s treatment 
assignment unless this could delay emergency treatment of the subject. The spons or must 
be notified within [ADDRESS_683155]’s medical record 
and electronic case report forms (eCRFs), with the reason for breaking the blind, the d ate 
  
Protocol CVL -751-PD-003 
Tavapadon  
 
Confidential  Page 33 of 90 Version  4.0: [ADDRESS_683156].  
6.4 Trial Treatment Compliance  
All IMP will be dispensed by [CONTACT_526408] p ersonnel. Subjects will be counseled on 
the importance of taking the IMP as directed (once daily in the morning, with or without 
food) at each clinic visit and will be instructed to bring all used and unused blister cards 
to each clinic visit. Accountabili ty and compliance (as assessed through self -reporting by 
[CONTACT_330208]) will be documented in the subject’s 
trial records. Deviation(s) from the prescribed dosage regimen should be recorded in the 
eCRF.  
If poor compli ance is encountered (eg, multiple missed doses resulting in <80% overall 
compliance at any point in the trial), discontinuation of the subject from the trial should 
be considered. Subjects who habitually miss visits or habitually attend visits outside of 
the protocol -defined visit window are also defined as noncompliant and should be 
considered for discontinuation. The medical monitor should be contact[CONTACT_330209] a subject’s lack of compliance merits discontinuation 
from the trial. 
6.[ADDRESS_683157] all medications and therapi[INVESTIGATOR_014] (including vaccines, 
over-the-counter or prescription medicines, vitamins, and/or herbal supplements) that are 
used by [CONTACT_112646] 30 days before the informed consent form (ICF) is signed 
through the end of the 4 -week Safety Follow -up Period (Week  31 or early termination). 
The investigator will also record all medications and therapi[INVESTIGATOR_330182] a 
subject for treatment of a n AE or that cause an AE through Week  [ADDRESS_683158] carbidopa/levo dopa or divided in at least 3 doses per day of extended -release 
carbidopa/levodopa capsules. Subjects must continue taking the carbidopa/levodopa at 
  
Protocol CVL -751-PD-003 
Tavapadon  
 
Confidential  Page 34 of 90 Version  4.0: 06 Jul 2023    
the same dose and frequency for the duration of the trial. No adjustment in the dose of 
frequency of carbid opa/levodopa is permitted during the study.  
Standard or extended -release levodopa/benserazide is allowed as an alternative to 
levodopa/carbidopa, where available.  
6.5.[ADDRESS_683159] of Medications Prohibited Before  the Trial  
 Medication  Washout Period  
1.  Moderate or strong CYP3A4 inducers or CYP3A4 inhibitors 
(refer to Section  10.6 [Appendix  6] for examples), except for 
topi[INVESTIGATOR_78086]  -- 
2.  Levodopa inhalation powder  >7 days before Baseline Visit  
3.  Dopamine agonists, including apomorphine  >14 days before Baseline Visit  
4.  Varenicline  >14 days before Baseline Visit  
5.  Nonselective MAO inhibitors, methyldopa, reserpi[INVESTIGATOR_050], or 
tricyclic antidepressants  >2 months before Screening Visit  
6.  Dopamine antagonists, such as neuroleptics/antipsychotics (eg, 
phenothiazines, butyrophenones, thioxanthenes), including 
haloperidol, trimethobenzamide, or domperidone for 
nausea/vomiting, metoclopramide, and quetiapi[INVESTIGATOR_123201]  >14 days before Baseli ne Visit  
7.  Atypi[INVESTIGATOR_16709], mood stabilizers (lithium or 
anticonvulsants), or prescription stimulants (amphetamine 
derivatives, methylphenidate, bupropi[INVESTIGATOR_2394], phentermine, 
phenylpropanolamine modafinil, mazindol)  
Note: use of certain anticonvulsants (eg, pregabalin) for 
medical reasons unrelated to seizures or psychiatric mood 
stabilization may be allowed after discussion with and approval 
by [CONTACT_7195].  >14 days before Baseline Visit 
(1 full cycle for long -acting depot 
antipsychotics)  
8.  Seda tives, hypnotics, antidepressants, or anxiolytics  No washout is required if dose has 
been stable for >90  days before the 
Baseline Visit; washout of 
>14 days if dosing was started or 
dose was changed ≤90  days before 
the Baseline Visit.  
9.  COMT inhibitors, MAO -B inhibitors, amantadine, 
istradefylline, or anticholinergic drugs if use was initiated 
≤90 days before the Baseline Visit  >14 days before Baseline Visit  
10.  Other investigational medications  >60 days before Screening Visit  
Abbreviations: COMT  = catech ol-O-methyl transferase, CYP = cytochrome P450, ICF = informed consent, 
MAO = monoamine oxidase.  
-- Not applicable. Any prior use is prohibited.  
  
Protocol CVL -751-PD-003 
Tavapadon  
 
Confidential  Page 35 of 90 Version  4.0: [ADDRESS_683160]’s 
continued participation in the trial in the event that initiation of therapy with a prohibited 
concomitant medication is deemed necessary, in the investigator’s opi[INVESTIGATOR_1649], for the 
treatment of a treatment -emergent adverse event (TEAE).  
  
Protocol CVL -751-PD-003 
Tavapadon  
 
Confidential  Page 36 of 90 Version  4.0: [ADDRESS_683161] of Medications Prohibited During th e Trial  
 Medication  
1.  Sedatives, hypnotics, antidepressants, and anxiolytics (unless dose has been stable for >90  days 
before the Baseline Visit and will remain stable for the duration of the treatment phase)  
Note: Short -term use of lorazepam (up to 4 mg/day), or its equivalent, for TEAEs of anxiety or 
insomnia may be permitted following consultation with and approval by [CONTACT_7195], but 
may not be taken within 12 hours prior to efficacy assessments during clinic visits. Use should be 
discontinu ed upon TEAE resolution.  
2.  Atypi[INVESTIGATOR_16709]  
3.  Dopamine antagonists, such as neuroleptics/antipsychotics (eg, phenothiazines, butyrophenones, 
thioxanthenes), including:  
 a. Haloperidol  
 b. Trimethobenzamide or domperidone (for nausea/vomiting)  
 c. Metoclopramide  
 d. Quetiapi[INVESTIGATOR_050] (for insomnia)  
4.  COMT inhibitors, MAO -B inhibitors, amantadine, istradefylline, or anticholinergic drugs (unless 
use was initiated >90 days before the Baseline Visit and dose will remain stable for the duration of 
the treatment phase)  
Note: Short -term use of scopolamine for TEAEs of nausea may be permitted following 
consultation with and approval by [CONTACT_7195], but may not be taken within 12 hours prior 
to efficacy assessments during clinic visits. Use should be disconti nued upon TEAE resolution.  
5.  Levodopa inhalation powder  
6.  Dopamine agonists, including apomorphine  
7.  Methyldopa  
8.  Moderate or strong CYP3A4 inducersa (refer to Section  10.6 [Appendix  6] for examples)  
9.  Moderate or strong CYP3A4 inhibitorsa (refer to Section  10.6 [Appendi x 6] for examples)  
10.  Mood stabilizers  
 a. Anticonvulsants  
 b. Lithium  
Note: Use of certain anticonvulsants (eg, pregabalin) for medical reasons unrelated to seizures or 
psychiatric mood stabilization may be allowed after discussion with and approval by [CONTACT_35011].  
11.  Nonselective MAO inhibitors  
12.  Prescription stimulants  
 a. Amphetamine derivatives  
 b. Bupropi[INVESTIGATOR_2394]  
 c. Mazindol  
 d. Methylphenidate  
 e. Modafinil  
 f. Phentermine  
 g. Phenylpropanolamine  
13.  Reserpi[INVESTIGATOR_050]  
14.  Tricyclic antidepressants  
  
Protocol CVL -751-PD-003 
Tavapadon  
 
Confidential  Page 37 of 90 Version  4.0: 06 Jul 2023    
15.  Varenicline  
16.  Zonisamide  
17.  Other investigational medications  
Abbreviations: COMT  = catechol -O-methyl transferase, CYP = cytochrome P450, MAO  = monoamine oxidase; 
TEAE = treatment -emergent adverse event.  
a. Except for topi[INVESTIGATOR_78086] . 
6.5.[ADDRESS_683162] the opportunity to receive 
open -label treatment with tavapadon in an open -label extension trial 
(Protocol  CVL -751-PD-004). Subjects who are ineligible or elect not to enter the 
open -label  extension trial will resume treatment with available antiparkinsonian 
medications at the discretion of and as determined by [CONTACT_9682].  
[ADDRESS_683163] DISCONTINUAT ION/WITHDRAWAL  
7.1 Discontinuation of Entire Trial  
If the sponsor terminates or suspends the trial for any reason, prompt notification will be 
given to investigators, Institutional Review Boards/Independent Ethics Committees 
(IRBs/IECs), and regulatory authorities in accordance with regulatory requirements.  
7.2 Discontinuation of Individual Site  
Participation of an individual trial site may be discontinued by [CONTACT_456], the 
investigator, or the IRB/IEC if judged to be necessary for medical, safety, regulatory, 
ethical, or other reasons consistent with applicable laws, regulations, and Good Clinical 
Practice (GCP). The investigator will notify the sponsor promptly if the trial is terminated 
by [CONTACT_35063]/IEC at the site.  
7.[ADDRESS_683164] who is not satisfied with 
  
Protocol CVL -751-PD-003 
Tavapadon  
 
Confidential  Page 38 of 90 Version  4.0: [ADDRESS_683165] may discontinue the IMP for any of the following reasons:  
• Adverse event  
• Death  
• Worsening of PD symptoms to such an extent that, in the judgment of the 
investigator, the subject requires additional anti-PD medications  
• Treatment with prohibited concomitant medications  
• Noncompliance with study schedule  
• Noncompliance with study drug  
• Withdrawal by [CONTACT_1130]  
• Pregnancy  
• Physician decision  
If a subject discontinues the IMP due to an AE, the investigator or ot her trial personnel 
will make every effort to follow the event until it has resolved or stabilized.  
All subjects have the right to withdraw consent for further participation in the trial at any 
time without prejudice. Subjects cannot withdraw consent for use of data that have 
already been collected as part of the trial but can withdraw consent for future 
participation. The investigator can also discontinue a subject from the trial at any time if 
medically necessary. Unless the subject provides written with drawal of consent or there 
is other written documentation by [CONTACT_444470]’s verbal intent 
to completely withdraw from the trial, subjects should be followed for all 
protocol -specified evaluations and assessments, if possible.  
Com plete withdrawal of consent requires a subject to refuse of ALL of the following 
methods of follow -up: 
• Participation in all follow -up procedures specified in the protocol (whether in -clinic 
or by [CONTACT_756])  
• Participation in a subset of protocol specified f ollow -up procedures (by a frequency 
schedule and method, as agreed by [CONTACT_330210])  
• Contact [CONTACT_330211], even if only by [CONTACT_756], to assess current 
medical condition, and obtain necessary medical or laboratory reports relevant to the 
trial’s objectives  
• Contact [CONTACT_330212](s) who has been designated in source records as 
being available to discuss the subject’s medical condition, even if only by [CONTACT_756], 
mail, or e -mail (eg, family, spouse, partner, legal representa tive [as defined per local 
regulations], friend, neighbor, or physician)  
  
Protocol CVL -751-PD-003 
Tavapadon  
 
Confidential  Page 39 of 90 Version  4.0: 06 Jul 2023    
• Access to medical information from alternative sources (eg, hospi[INVESTIGATOR_307]/clinic medical 
records, referring doctor’s notes, public records, dialysis, transplantation or vital 
registries, s ocial media sources)  
Withdrawal of consent is a critical trial event and, therefore, should be approached with 
the same degree of importance and care as is used in initially obtaining informed consent. 
The reasons for a subject’s intended withdrawal need t o be completely understood, 
documented, and managed to protect the rights of the subject and the integrity of the trial. 
A subject may initially express the desire to interrupt, modify, or discontinue 
administration of the IMP, which is not equivalent to a  complete withdrawal of consent 
for further participation. A subject may, however, indicate that further trial participation 
is creating a burden on his or her work, school, or social schedule. Therefore, the 
investigator should determine if the subject ca n continue participation in the trial if 
modifications to his/her treatment and/or schedule of assessments can be accommodated. 
Only subjects who withdraw their permission for all of the above methods of follow -up 
are considered to have completely withdraw n their consent to participate in the trial.  
Details on the withdrawal of consent for the optional banked biospecimen sample are 
provided in the separate ICF for that sample.  
7.[ADDRESS_683166] fails to return to the clinic for a required 
trial visit:  
• The site must attempt to contact [CONTACT_155979]/or should 
continue in the trial.  
• Before a subject is deemed lost to follow up, the investigator or designee must make 
every effort to regain contact [CONTACT_1155] (where possible, [ADDRESS_683167]’s last known mailing address or local 
equivalent methods). These conta ct attempts should be documented in the subject’s 
medical record.  
• Should the subject continue to be unreachable, he/she will be considered to have 
withdrawn from the trial.  
8 TRIAL ASSESSMENTS AN D PROCEDURES  
Trial procedures and their timing are summarized in the Schedule of Assessments 
(Table  2). Protocol waivers or exemptions are not allowed.  
  
Protocol CVL -751-PD-003 
Tavapadon  
 
Confidential  Page 40 of 90 Version  4.0: [ADDRESS_683168] be completed and reviewed to confirm that potential 
subjects meet all eligibility criteria. Data collected as part of the screening process may 
be submitted to sponsor/clinical research organization (CRO) in order to facilita te 
eligibility assessment. Protocol waivers or exemptions are not allowed. The investigator 
will maintain a screening log to record details of all subjects who are screened and to 
confirm eligibility or record reasons for screening failure, as applicable.  
Procedures that are conducted as part of the subject’s routine clinical management (eg, 
blood count) and that are obtained before the ICF is signed may be used for screening or 
baseline purposes provided the procedures meet the protocol -specified criteria  and were 
performed within the time frame defined in the Schedule of Assessments ( Table  2). 
As part of the screening procedures, the investigator will a ssess the severity of each 
subject’s PD symptoms using the modified Hoehn and Yahr scale ( Hoehn and Yahr, 
1967 ; Goetz et al, 2004 ) on which:  
Stage  Definition  
1 = Unilateral involvement only  
1.5 =  Unilateral and axial involvement  
2 = Bilateral involvement without impairment of balance  
2.5 =  Mild bilateral disease with recovery on pull test  
3 = Mild to moderate bilateral disease; some postural instability; physically 
independent  
4 = Severe disability; still able to walk or stand unassisted  
5 = Wheelchair bound or bedridden unless added  
Subjects must have a modified Hoehn and Yahr stage of 2, 2.5, or 3 for inclusion in the 
trial. 
The investigator will also administer the Montreal Cognitive Assessment (MoCA) to 
detect the subject’s level of cognitive impairment ( Nasreddine et al, 2005 ). The MoCA is 
administered over approximately [ADDRESS_683169] thinking. The total possible score is 30, with any 
score greater than 25  considered normal. Scores of 25 or less are considered to be an 
  
Protocol CVL -751-PD-003 
Tavapadon  
 
Confidential  Page 41 of 90 Version  4.0: 06 Jul 2023    
indication of some form of cognitive impairment. Subjects with a MoCA score <26 will 
not be eligible for the trial. 
8.2 Efficacy Assessments  
The planned time points for efficacy assessments are shown in the Schedule of 
Assessments ( Table  2). At each clinic visit, efficacy assessments should be completed 
first, followed by [CONTACT_330214].  
8.2.1  Hauser Diary  
The Hauser diary assesses patient -defined motor function status over a period and 
provides a tool for assessment of change in “off” time and “on” time with troublesome 
dyskinesia ( Hauser et al, 2000 ). The Hauser diary asks patients to rate their mobility for 
each [ADDRESS_683170] th eir status for the majority of the period in 1 of 
5 categories as: “on” time without dyskinesia, “on” time with nontroublesome dyskinesia, 
“on” time with troublesome dyskinesia, “off” time, or asleep.  
During the Screening Period, subjects will be trained i n the use of the home diary (Hauser 
diary), and subjects and investigators (or qualified designee) will independently complete 
concordance testing on the Hauser diary (full details and requirements for conduct and 
successful completion of concordance testi ng are provided in the appropriated 
protocol -specific manual). Subjects who successfully meet the concordance testing 
criteria will complete the Hauser diary at home on at least 2 consecutive days (24 -hour 
periods) within the [ADDRESS_683171] diary entries at home at 30 -minute intervals for 24  hours on 2 
consecutive days within the 7  days before randomization at the Baseline Visit and at 
30-minute intervals for 24  hours on 2 consecutive days within the 7  days before eac h 
postbaseline clinic visit.  
8.2.2  Movement Disorder Society -Unified Parkinson’s Disease Rating 
Scale  
The MDS -UPDRS ( Goetz et al, 2008 ) is a multidimensional scale that assesses the motor 
and nonmotor impacts of PD across 4 parts. Th e scale is completed using a combination 
of physician and patient assessments and a collection of information from the patient or 
caregiver:  
• Part I, nonmotor aspects of experiences of daily living, comprises 13  items, 6 of 
which are rated by [CONTACT_099] (Part  IA) and 7 of which are rated by [CONTACT_102] 
(Part  IB).  
• Part II, motor aspects of experiences of daily living, comprises 13  items that are 
rated by [CONTACT_102]. The 13 items in Part  II and the 7  items in Part  IB constitute the 
patient questionnaire p ortion of the MDS -UPDRS.  
  
Protocol CVL -751-PD-003 
Tavapadon  
 
Confidential  Page 42 of 90 Version  4.0: 06 Jul 2023    
• Part III, motor examination, comprises 18  items that are assessed by [CONTACT_093] 
(resulting in 33 scores by [CONTACT_330215]).  
• Part IV, motor complications, comprises 6  item (3  items for dyskinesia and 3  items 
for fluctuation) and requires the physician to use historical and objective information 
to assess dyskinesia and motor fluctuations.  
Each item is rated on a scale from 0 to 4 on which 0  = normal, 1  = slight, 2  = mild, 
3 = moderate, and 4  = severe. 
The same indi vidual should perform the ratings for an individual subject throughout the 
course of the trial. The postbaseline MDS -UPDRS assessments Parts I, II, and III should 
be conducted approximately [ADDRESS_683172] dose of L -Dopa on the day of the 
clinic visit.  
8.2.3  39-Item Parkinson’s Disease Questionnaire  
The 39 -item Parkinson’s Disease Questionnaire (PDQ -39) is the most thoroughly 
validated and extensively used self -report measure for the assessment of health -related 
quality of life in people with PD. The  questionnaire measures 39  items, which assess 
8 domains of health: mobility (10  items), activities of daily living (6  items), emotional 
well-being (6  items), stigma (4  items), social support (3  items), cognitions (4  items), 
communication (3  items), and bo dily discomfort (3  items) ( Peto et al, 1998 ). Each item is 
scored on the following scale: 0=never, 1=occasionally, 2=sometimes, 3=often, and 
4=always. Items in each subscale and the total scale can be summarized into an index an d 
transformed linearly to a scale from 0 (perfect health as assessed by [CONTACT_330217]) to 100 
(worst health as assessed by [CONTACT_330217]).  
8.2.4  EuroQol 5 Dimension 5 Level  
The EuroQol 5 Dimension 5 Level (EQ -5D-5L) is a patient -reported outcome that 
measures healt h in 5 dimensions. It is a widely used survey instrument for measuring 
economic preferences for health states, is applicable to a wide variety of health conditions 
and treatments, and provides a simple descriptive profile and a single index value for 
healt h status ( Herdman et al, 2011 ). The EQ -5D-5L consists of a descriptive system and a 
visual analog scale (VAS).  
The descriptive system comprises 5 dimensions: mobility, self -care, usual activities, 
pain/discomfort, and anxiety /depression. Each dimension has 5 levels: no problems, 
slight problems, moderate problems, severe problems, and extreme problems. The patient 
is asked to indicate his or her health state by [CONTACT_330218] 5 dimensions. This decision results if a 1 -digit number that 
expresses the level that was selected for that dimension. The digits for the 5  dimensions 
are combined into a 5 -digit number that describes the patient’s health state.  
The EQ -5D-5L VAS record s the patient’s self -rated health on a vertical VAS on which 
the endpoints are labeled “the best health quality that you can imagine” and “ the worst 
  
Protocol CVL -751-PD-003 
Tavapadon  
 
Confidential  Page 43 of 90 Version  4.0: 06 Jul 2023    
health quality that you can imagine.” The VAS can be used as a quantitative measure of 
health outcome that  reflects the patient’s own judgment.  
8.3 Safety Assessments  
Planned time points for all safety assessments are provided in the Schedule of 
Assessments ( Table  2).  
Safety assessments should be performed after all efficacy assessments have been 
completed. Assessments should be performed in the following order:  
• Epworth Sleepi[INVESTIGATOR_7110] (ESS)  
• Questionnaire for Impulsive -Compulsive Disorders in Parkinson’s Disease  Rating 
Scale (QUIP -RS) 
• Columbia -Suicide Severity Rating Scale (C -SSRS)  
• Physical and neurological examinations  
• Vital signs  
• Electrocardiograms  
• Blood specimen collection  
• Other procedures (eg, concomitant medications, AEs): all other procedures may be 
obtain ed before or after blood specimen collection  
8.3.1  Epworth Sleepi[INVESTIGATOR_330184] a scale that is intended to measure daytime sleepi[INVESTIGATOR_008] ( Johns, 1991 ). It 
assesses the likelihood of dozing off or falling asleep in the following common situations: 
sitting and reading, sitting inactive in a public place (eg, in a meeting, theater, dinner 
event), as a passenger in a car for an hour or more without stoppi[INVESTIGATOR_48908] a break, lying 
down to rest when circumstances permit, sitting and talkin g to someone, sitting quietly 
after a meal without alcohol, and in a car while stopped for a few minutes in traffic or at a 
light. Each situation is rated as 0=would never nod off, 1=slight chance of nodding off, 
2=moderate chance of nodding off, or 3=high  chance of nodding off. A score ≥10 
indicates that the patient may need to get more sleep, improve sleep practices, or seek 
medical attention to determine why he or she is sleepy.  
8.3.2  Questionnaire for Impulsive -Compulsive Disorders in Parkinson’s 
Disease -Rating Scale  
The QUIP -RS is a global screening instrument that assesses ICDs and related disorders 
(punding, hobby[CONTACT_128053], and dopamine dysregulation syndrome) in patients with PD 
  
Protocol CVL -751-PD-003 
Tavapadon  
 
Confidential  Page 44 of 90 Version  4.0: 06 Jul 2023    
(Weintraub et al, 2012 ). The QUIP -RS has 4 primary questions that pertain to commonly 
reported thoughts, urges/desires, and behaviors associated with ICDs, each of which is 
applied to 4 ICDs (compulsive gambling, buying, eating, sexual behavior) and 3 related 
disorders (medication use, punding, and hobby[CONTACT_832] m).  
The QUIP -RS uses a 5 -point Likert scale (score 0 –4 for each question) to gauge the 
frequency of behaviors. Patients are instructed to answer questions based on behaviors 
that occurred in the preceding 4 weeks or during any 4 -week period in a designate d time 
frame and are provided with a brief description of the behaviors that are being assessed 
and with a brief description of the Likert scale categories for frequency (eg, 0=never [not 
at all], 1=rarely [infrequently or 1 day/week]). Scores for each ICD  and related disorder 
range from 0 to 16, with a higher score indicating greater severity (frequency) of 
symptoms. The total QUIP -RS score for all ICDs and related disorders combined ranges 
from 0 to 112.  
8.3.3  Columbia -Suicide Severity Rating Scale  
Suicidality will be monitored during the trial using the C -SSRS. This semi -structured 
interview was originally developed to evaluate the link between antidepressants and 
suicidal behavior and ideation in youth and AEs from pediatric clinical trials ( Posner et 
al, 2011 ). It was designed to quantify the severity of suicidal ideation and behavior. Trial 
personnel who administer the C -SSRS must complete the appropriate training and have 
valid certification. Training on the scale will be provid ed via the sponsor.  
This trial will use the “Baseline/Screening” and “Since Last Visit” versions of the scale. 
The “Baseline/Screening” version, which assesses the lifetime experience of the subject 
with suicide events and suicidal ideation and the occurre nce of suicide events or ideation 
within a specified time period prior to entry into the trial, will be completed for all 
subjects at screening to determine eligibility and confirmed at baseline. Any subject with 
active suicidal ideation or suicidal behavi ors within the last [ADDRESS_683173] 2 years, or who in the clinical judgment of the investigator presents a 
serious risk of suicide should be excluded from the trial ( Section  5.2, exclusion  8). 
The “Since Last Visit” C -SSRS form will be completed at all visits after screening and 
baseline. The investigator will review the results of the “Since Last Visit” C -SSRS during 
the trial to determine whether it is safe for the subject to continue in the trial. If a subject 
demonstrates potential suicidal ideation associated with actual intent or method or plan as 
indicated by “YES” answers on item 4 or 5 of the C -SSRS, the investigator will e valuate 
whether a risk assessment by a qualified mental health professional (or the investigator 
alone if the investigator is a qualified mental health professional) is needed and whether 
the subject should continue in or be discontinued from the trial.  
8.3.[ADDRESS_683174] of measurement of height (screening only) 
and weight and a review of the following body systems: head, ears, eyes, nose, mouth, 
skin, heart and lungs, lymph nodes, and gastro intestinal and musculoskeletal systems.  
  
Protocol CVL -751-PD-003 
Tavapadon  
 
Confidential  Page 45 of 90 Version  4.0: [ADDRESS_683175]’s mental status 
(level of consciousness, orientation, speech, memory, etc), cranial nerves, motor (muscle 
appearance, tone, strength and refl exes), sensation (including Romberg sign), 
coordination, and gait.  
Height will be measured with a stadiometer, measuring stick, or tape.  
The following guidelines will aid in the standardization of body weight measurements:  
• The same scale should be used to  weigh a given subject each time, if possible.  
• Scales should be calibrated and reliable; scales should be at zero just prior to each 
subject’s weigh -in session.  
• A subject should void prior to being weighed and be minimally clothed (ie, no shoes 
or heavy ov ergarments).  
• Weight should be recorded before a subject’s meal and at approximately the same 
time at each visit.  
The investigator (or designee) is responsible for performing the physical and neurological 
examinations. If the appointed designee is to perfor m these examinations, he or she must 
be permitted by [CONTACT_526409]. Whenever possible, the same individual should perform all physical and 
neurological examinations.  
Any condition  present at the posttreatment physical or neurological examination that was 
not present at the baseline examination should be documented as an AE and followed to a 
satisfactory conclusion.  
8.3.5  Vital Signs  
Vital signs include systolic and diastolic blood pressu res, heart rate, and body 
temperature. Duplicate readings of blood pressure and heart rate will be obtained in 
supi[INVESTIGATOR_050] (after [ADDRESS_683176]) and 1 measurement of blood pressure and heart rate will 
be obtained on standing (2 minutes after rising from sup ine to standing). The duplicate 
values will be individually recorded, and the values will be averaged by [CONTACT_330220]. Body temperature will be obtained once, at the time of the first 
blood pressure measurement.  
Additional info rmation related to measurement of blood pressure and heart rate is 
provided in the appropriate protocol -specific manuals.  
8.3.[ADDRESS_683177] 5  minutes. A triplicate 
set of ECGs is 3  consecutive ECGs collected 1 to 2  minutes apart over a 5 -minute period.  
  
Protocol CVL -751-PD-003 
Tavapadon  
 
Confidential  Page 46 of 90 Version  4.0: [ADDRESS_683178] dose of IMP on Day  1, and a single ECG will 
be obtained ~[ADDRESS_683179] prior to the time of collection of the PK 
blood sample.  
Additional 12 -lead ECGs may be obtained at the investigator’s discretion and should 
always be obtained in the event of an early termination.  
The ECG results  will be evaluated at the investigational site to determine the subject’s 
eligibility and to monitor safety during the trial. The principal investigator (or qualified 
designee) will review, sign, and date each ECG reading, noting whether or not any 
abnorma l results are of clinical significance. The ECG will be repeated if any results are 
considered to be clinically significant. A central ECG service will be used for reading all 
ECGs to standardize interpretations for the safety analysis.  
If, during screening, any abnormal ECG finding is deemed medically significant 
(impacting the safety of the subject or the interpretation of the trial results) or meets an 
exclusion criterion (see Section  5.2), the subject should be excluded from the trial. 
Medically significant or exclusory abnormal results on an ECG at screening should be 
repeated with [ADDRESS_683180]. For subjects with a QTcF >[ADDRESS_683181] will be 
excluded if the QTcF intervals reported by [CONTACT_330221] >450 msec for 2 or 
more of the 3 ECG recordings, unless due to ventricular pacing. If, at the Baseline Visit, 
the QTcF interval is >[ADDRESS_683182] during the 
treatment period (which will be confirmed by [CONTACT_330222]) and, in these cases, the 
medical monitor should be consulted on the appropriateness of the subject continuing in  
the trial.  
8.3.[ADDRESS_683183] of clinical laboratory tests that are to be performed is provided in Section  10.2 
(Appe ndix 2). All protocol -required laboratory assessments must be conducted in 
accordance with the laboratory manual and the Schedule of Assessments ( Table  2). 
The investigator must review the laboratory report, document this review, and record any 
clinically relevant changes occurring during the trial in the AE section of the eCRF. The 
laboratory reports must be filed with the source documents. Clinically significant 
abnormal laboratory findings are those that are not associated with the underlying 
  
Protocol CVL -751-PD-003 
Tavapadon  
 
Confidential  Page 47 of 90 Version  4.0: [ADDRESS_683184]'s condition.  
All laboratory tests with values that are considered clin ically significantly abnormal 
during participation in the trial should be repeated until the values return to normal, to  
baseline, or are no longer considered clinically significant by [CONTACT_43210]. If such values do not return to n ormal/baseline within a period of time judged 
reasonable by [CONTACT_093], the etiology should be identified and the sponsor notified.  
All protocol -required laboratory assessments, as defined in Section  10.2 (Appendix  2), 
must be conducted in accordance with the laboratory manual and the Schedule of 
Assessments ( Table  2). 

  
Protocol CVL -751-PD-003 
Tavapadon  
 
Confidential  Page 48 of 90 Version  4.0: [ADDRESS_683185]  
The definitions of an AE and SAE are provided in Section  10.3 (Appendix  3). The AESI 
for this trial are defined in Section  8.4.[ADDRESS_683186] (or, when appropriate, by a caregiver, 
surrogate, or the subject's legally authorized representative, as defined per local 
regulations).The investigator and any qualified designees are responsible for detecting, 
documenting, and  recording events that meet the definition of an AE, SAE, or AESI and 
remain responsible for following up SAEs/AESI, considered related to the trial 
intervention or trial procedures, or cause the subject to discontinue IMP (see Section  7.3). 
8.4.1  Time Period and Frequency for Collecting AE and SAE/AESI 
Information  
All AEs and SAEs/AESIs will be recorded from the first dose of IMP until follow -up 
contact [CONTACT_469110] e time points specified in the Schedule of Assessments ( Table  2). 
Medical occurrences that begin before the start of IMP dosing but after obtaining 
informed consent will be recorded as medical and/or psychiatric history.  
All SAEs/AESI will be recorded and reported to the sponsor or designee immediately and 
under no circumstance should this exceed 24 hours, as indicated in Section  10.3 
(Appendix  3). The investigator will submit any updated SAE/AESI data to the sponsor 
within [ADDRESS_683187] has been discharged from the trial, or AESI and he/she 
considers the event to be reasonably related to the trial intervention or trial participation, 
the investigator must promptly notify the sponsor.  
8.4.2  Method of Detecting AEs and SAEs/AESI  
The method of recording, evaluating, and assessing causality of AEs and SAEs/AESI and 
the procedures for comp leting and transmitting SAE/AESI reports are provided in 
Section  10.3 (Appendix  3). 
Care will be taken not to introduce bias when detecting AEs and /or SAEs/AESI. 
Open -ended and nonleading verbal questioning of the subject is the preferred method to 
inquire about AE occurrences.  
8.4.3  Follow -up of AEs and SAEs/AESI  
After the initial AE/SAE/AESI report, the investigator is required to proactively follow 
each subject at subsequent visits/contacts. All SAEs/AESI will be followed until 
  
Protocol CVL -751-PD-003 
Tavapadon  
 
Confidential  Page 49 of 90 Version  4.0: [ADDRESS_683188] to follow -
up (as defined in Section 7.4). Further information on follow -up procedures is given in  
Section  10.3 (Appendix  3). 
8.4.4  Regulator y Reporting Requirements for SAEs/AESI  
Prompt notification by [CONTACT_330225]/AESI is essential so that 
legal obligations and ethical responsibilities towards the safety of subjects and the safety 
of a trial intervention under clinical investigation are met.  
The sponsor has a legal responsibility to notify both the local regulatory authority and 
other regulatory agencies about the safety of a trial intervention under clinical 
investigation. The sponsor will comply with country -specific regulatory requirements 
relating to safety reporting to the regulatory authority, IRBs/IECs, and investigators.  
Investigator safety reports must be prepared for suspected unexpected serious adverse 
reactions (S[LOCATION_003]R) according to local regulatory re quirements and sponsor policy and 
forwarded to investigators as necessary.  
An investigator who receives an investigator safety report describing an SAE/AESI or 
other specific safety information (eg, summary or listing of SAEs/AESI) from the 
sponsor will re view and then file it along with the Investigator’s Brochure and will notify 
the IRB/IEC, if appropriate according to local requirements.  
8.4.[ADDRESS_683189] dose.  
If a pregnancy is reported, the investigator should inform the sponsor within 24 hours of 
learning of the pregnancy and should follow the procedures outlined in Section  10.4 
(Appendix  4). 
Abnormal pregnancy outcomes (eg, spontaneous abortion, fetal death, stillbirth, 
congenital anomalies, ectopic pregnancy) are considered SAEs.  
8.4.[ADDRESS_683190]  
[IP_ADDRESS]  Adverse Events Potentially Related to Abuse  
A key objective of the Abuse Potential Monitoring Plan (APMP) is to monitor for 
instances of abuse or diversion of the trial medication and other psychoactive substances.  
In add ition to monitoring for irregularities in medication handling, AEs that may be 
suggestive of a developi[INVESTIGATOR_330185]. As part of the 
APMP, medication handling irregularities (MHIs) must be reported, and AEs related to 
  
Protocol CVL -751-PD-003 
Tavapadon  
 
Confidential  Page 50 of 90 Version  4.0: [ADDRESS_683191] to additional 
monitoring (ESAMs), with detailed narratives.  
Investigators and site staff at each trial site will be trained on reporting potentially abuse 
related AEs (eg, recording a  description of the event in the subject’s own words in the 
source documents as well as the eCRF, in addition to the clinical term, and to be aware 
that a subject’s report may encompass more than one event and that these should be 
recorded separately). The  investigators will be provided with examples of potentially 
abuse -related AEs and trained on how to handle such events (eg, additional monitoring).  
While the investigators will be provided with examples of AE terms as a guide during 
trial conduct, the ana lysis of potentially abuse -related AEs will be based on a search by 
[CONTACT_308708] (MedDRA) 
terms, all verbatim terms, and any open text fields within the AE data to identify text 
strings suggestive  of abuse potential, consistent with US Food and Drug Administration 
(FDA) guidance (Guidance for Industry: Assessment of Abuse Potential of Drugs, 
January 2017).  
Complete details, including documenting and reporting procedures, examples of 
potentially abu se-related terms and guidance for the training of investigators and trial site 
staff are provided in the APMP.  
[IP_ADDRESS]  Abnormal Liver Function Tests  
The finding of an elevated value for alanine aminotransferase (ALT) or aspartate 
aminotransferase (AST) of >3  × the  upper limit of normal (ULN) in combination with 
either an elevated value for total bilirubin >2 × ULN or clinical jaundice in the absence of 
cholestasis or other causes of hyperbilirubinemia is considered to be an indicator of 
severe liver injury. Therefo re, investigators must report the occurrence of either of the 
following as AESI to the sponsor with 24 hours:  
• Treatment -emergent value of >3 × ULN for ALT or AST and >2 × ULN for total 
bilirubin  
• Treatment -emergent value of >3 × ULN for ALT or AST and clini cal jaundice  
Brief narratives will be written for any subjects who experience abnormalities in liver 
function tests that meet the criteria specified above.  
[IP_ADDRESS]  Adverse Events Leading to Discontinuation  
Any AE that leads to discontinuation of IMP or from the tr ial will be classified as an 
AESI. Brief narratives will be written for subjects who discontinue IMP or from the trial 
because of AEs.  
  
Protocol CVL -751-PD-003 
Tavapadon  
 
Confidential  Page 51 of 90 Version  4.0: [ADDRESS_683192] been evaluated subjects with PD 
(Trial  B7601005) . Across all doses (5, 15, and 25  mg QD), nausea, vomiting, headache, 
dizziness, and abnormal dreams were the most commonly reported TEAEs. A 
dose-related increase was observed between the 15  mg QD (n=11) and 25  mg QD (n=19) 
doses in the percentage of subj ects who experienced gastrointestinal -related TEAEs (27% 
vs 58%), in particular, nausea (27% vs 42%) and vomiting (9.1% vs 21.1%), and in the 
percentage of subjects who discontinued from the trial due to gastrointestinal TEAEs (0% 
vs 16%). Other TEAEs were  reported in comparable percentages of subjects. Based on 
these findings, as well as on PK findings, which showed a less -than-dose-proportional 
increase in exposure between the 15 and 25  mg doses (consistent with the 
moderate -to-low solubility of tavapadon  at the pH of the gastrointestinal tract of 6.5), 
15 mg QD was identified as the maximum dose in this trial (see also Section  4.3). 
Any dose >15  mg of  tavapadon (maximum dose in this trial) within the same calendar 
day will be considered an overdose. There is no specific antidote for overdose with 
tavapadon. In the event of an overdose, the investigator should:  
1. Contact [CONTACT_10990]  
2. Closely monitor the subject for any AE/SAE/AESI and laboratory abnormalities  
3. Document the quantity of the excess dose, as well as the duration of the 
overdose, in the eCRF  
Decisions regarding dose interruptions or modifications will be made by [CONTACT_330226].  
8.6 Pharmacokinetics  
Blood samples for measurement of plasma concentrations of tavapadon and its major 
metabolite (if required) will be collected ~[ADDRESS_683193] after 
ECG acquisition at each time point, as shown in the Schedule of Activities ( Table  2). The 
date and time of the most recent dose, the dose amount, and the time of the blood draw 
will be recorded. Instructions for the collection and handling of biological samples will 
be provided by [CONTACT_456].  
Plasma samples will be processed, stored, and shipped to the bioanalytical facility 
according to the instructions that will be provided to the investigator in advance of the 
trial. A fully validated bioanalytical method will be used to quantitate plasma 
concentrations of tavapadon and its major metabo lite (if required).  
Drug concentration information will not be reported to investigative sites or blinded 
personnel until the trial has been unblinded.  
  
Protocol CVL -751-PD-003 
Tavapadon  
 
Confidential  Page 52 of 90 Version  4.0: 06 Jul 2023    
8.7 Future Biospecimen Research  
Studying the variation in genetic markers and other biomarkers may help to explain some 
of the variability in response seen with some drugs among different individuals. This is 
referred to as pharmacogenomic/biomarker research. Comparing the DNA, RNA, protein, 
and metabolite variation patterns of subjects who respond well and tho se who respond 
poorly to treatment may help to better define the most appropriate group of subjects in 
which to target a given treatment. Collecting biospecimens for exploratory 
pharmacogenomic/biomarker analyses and retaining them at Cerevel makes it poss ible to 
better understand the drug’s mechanism of action and to seek explanations for differences 
in, for example, exposure, efficacy, tolerability, or safety not anticipated prior to the 
beginning of this trial.  
Banked biospecimen samples will be collecte d from subjects who consent to this sample 
collection on a separate ICF. Research performed on these samples may include genetic 
analyses (DNA), gene expression profiling (RNA), proteomics, metabolomics and/or the 
measurement of other analytes. Such resear ch is for biomarker testing to address 
emergent questions not described elsewhere in the protocol (as part of the main trial) and 
will only be conducted on specimens from appropriately consented subjects.  
9 STATISTICAL CONSIDER ATIONS  
9.1 Statistical Hypotheses  
The primary efficacy endpoint is the change from baseline in “on” time without 
troublesome dyskinesias. The hypothesis of interest is a [ADDRESS_683194] of superiority 
comparing tavapadon (CVL) to placebo:  
H0: µ placebo  = µ CVL -751 vs H 1: µ placebo  ≠ µ CVL -751 
9.2 Sample Size Determination  
A sample size of 184 subjects per group (total, 368 subjects) will provide at least 90% 
power to detect a change in the primary outcome measure (change from baseline in “on” 
time without troublesome dyskinesia) of [ADDRESS_683195] deviation of 2.5, a 
2-sided alpha level = 0.049, and assuming a 27% dropout rate.  
In the event of higher than anticipated early terminations due to COVID -19 or other 
reasons, Cerevel may extend enrollment in order to maintain the planned statistical 
power.  
9.3 Populations for Analyses  
The analysis populations are defined ( Table  8). 
  
Protocol CVL -751-PD-003 
Tavapadon  
 
Confidential  Page 53 of 90 Version  4.0: [ADDRESS_683196] 
1 measurable tavapadon (CVL -751) 
concentration  PK analysis  
Abbreviations: FAS = full analysis set, IMP = investigational medicinal product, ITT = intent -to-treat, 
mITT = modified intent -to-treat, PK = pharmacokinetic.  
9.4 Statistical Analyses  
Descriptive statistical methods will be used to summarize the data from this trial, with 
statistical testing performed for the efficacy endpoints. Unless stated ot herwise, the term 
“descriptive statistics” refers to number of subjects (n), mean, median, standard 
deviation, minimum, and maximum for continuous data, and frequencies and percentages 
for categorical data. All available data for enrolled subjects will be listed by [CONTACT_1130]. 
Unless otherwise noted, the data will be sorted first by [CONTACT_526410].  
All statistical analyses will be conducted with the SAS® System, version 9.[ADDRESS_683197] populations that will be used in the analysis and procedures for 
addressing missing, unused, and spurious data.  
9.4.1  Efficacy Analyses  
The analys is of the primary and each secondary endpoint ( Table  9) will include the 
comparison of tavapadon versus placebo. The hypothesis testing will be done in 
hierarchical order from the primary endpoint onward. To control for any potential 
inflation of Type I error that may be incurred from the interim analysis, the primary 
  
Protocol CVL -751-PD-003 
Tavapadon  
 
Confidential  Page 54 of 90 Version  4.0: 06 Jul 2023    
hypothesis will be tested at an α level of 0.049 (2 -sided) to ensure that the overall Type  I 
error rate is below 0.05. Subsequent testing in the secondary endpoints will be conducted 
at an α level of 0.05 (2 -sided).  
  
Protocol CVL -751-PD-003 
Tavapadon  
 
Confidential  Page 55 of 90 Version  4.0: 06 Jul 2023    
Table  9 Efficacy Analysis  
Endpoint  Statistical Analysis Methods  
Primary and  
Key Secondary  The primary endpoint (change from baseline to endpoint in “on” time without 
troublesome dyskinesia) and the key secondary endpoint (change from baseline to 
endpoint in “off” time) will be analyzed using an MMRM on the mITT population. 
This estimand will be based on th e 2-day average of the self -completed Hauser diary 
from each postbaseline visit. A hypothetical strategy will be used to address the 
intercurrent events of discontinuation or use of prohibited medications with the data 
post intercurrent events treated as c ensored. The baseline value will be included as a 
covariate, and the treatment group (tavapadon or placebo), visit, and interaction 
between treatment group and visit will be included as fixed factors in the MMRM. 
The difference between tavapadon versus pla cebo at endpoint will be estimated based 
on the LSMeans from the MMRM. The key secondary endpoint will be analyzed in a 
similar manner.  
 Sensitivity analyses for the primary and secondary endpoints will be conducted with 
different assumptions on missing m echanism. Sensitivity analysis will also be 
conducted on the endpoint completer set with MMRM.  
Secondary and 
Other  Continuous secondary and other endpoints (MDS -UPDRS, EQ -5D-5L index and VAS 
scores and PDQ -39 score) will be analyzed in a manner similar to  that used for the 
primary and key secondary efficacy endpoints. Categorical endpoints will be analyzed 
on the mITT population using the SAS® GLIMMIX procedure for binomial data with 
logit link. This generalized linear mixed model analysis will include res ponse data 
from each postbaseline visit that occurs before discontinuation of treatment or addition 
of rescue medication through endpoint. The model will include the treatment group, 
visit, and interaction between treatment group and visit. An unstructured  covariance 
structure will be used for the repeated measures. If the model fails to converge with 
the unstructured covariance structure, the heterogeneous Toeplitz structure or further 
reduced covariance structure may be used instead. The odds ratio for th e treatment 
difference, 95% CIs for the odds ratio, and p -value will be provided.  
Abbreviations: CI = confidence interval, EQ -5D-5L = EuroQol 5 Dimension 5 Level, mITT  = modified 
intent -to-treat, MDS -UPDRS = Movement Disorder Society – Unified Parkinson’s  Disease Rating Scale, 
LSMean  = least squares mean, mITT  = modified intent to treat, MMRM  = Mixed Model for Repeated Measures, 
PDQ -39 = 39 -Item Parkinson’s Disease Questionnaire, VAS  = visual analog scale.  
9.4.2  Safety Analyses  
All safety analyses ( Table  10) will be performed on the full analysis set (FAS). Should 
any subjects receive a treatment other than their randomized treatment, the treatment as 
received wil l be used in the safety presentation.  
  
Protocol CVL -751-PD-003 
Tavapadon  
 
Confidential  Page 56 of 90 Version  4.0: 06 Jul 2023    
Table  10 Safety Analysis  
Endpoint  Statistical Analysis Methods  
TEAEs, 
including 
abuse -related 
AEs and AEs 
related to MHIs  TEAEs will be coded according to MedDRA and summarized by [CONTACT_17673], 
system organ class, and preferred term. Additional summaries by [CONTACT_12917], 
severity, relationship to IMP, and dose at the time of onset will also be prepared.  
Other safety  The C -SSRS, ESS, QUIP -RS, laboratory data, vital sign data, and ECG data will be 
summarized with descriptive statistics.  
Abbreviations: AE  = adverse events, C -SSRS = Columbia -Suicide Severity Rating Scale, 
ECG  = electrocardiogram, ESS  = Epworth Sleepi[INVESTIGATOR_7110], IMP  = investigational medicinal product, 
MedDRA  = Medical Diction ary for Regulatory Activities, MHIs  = medication handling irregularities, 
QUIP -RS = Questionnaire for Impulsive -Compulsive Disorders  – Rating Scale, 
TEAE  = treatment -emergent adverse event.  
9.4.3  Other Analyses  
Plasma concentrations of tavapadon and its major m etabolite (if required) will be 
summarized by [CONTACT_2715], visit, and nominal time (if applicable). All PK exposure -response 
analyses will be described in a separate PK analysis plan that will be finalized before 
database lock.  
Plasma concentrations will also be  pooled with data from other trials in a population PK 
analysis to describe the time course of plasma concentrations of tavapadon and the 
influence of covariates (eg, body weight, age, sex, race, concomitant medications) on PK 
parameters. The results of po pulation PK analysis and response -exposure analyses will be 
presented separately from the main clinical study report (CSR).  
9.5 Interim Analysis  
Given that the assumptions for the sample size were based on a preliminary study using a 
different dosing schedule,  it is unknown if these assumptions are appropriate for this 
study as designed. To this end, an interim analysis of the primary efficacy endpoint will 
be included to assess the adequacy of the overall sample size relative to achieving the 
study objectives.  This analysis will be conducted by [CONTACT_526411] (IARC), which may make a recommendation to increase the overall 
sample size up to a maximum of 528  subjects. Full details and rules for the IARC and 
planned interim analys is will be provided in a separate IARC charter and in the statistical 
analysis plan.  
  
Protocol CVL -751-PD-003 
Tavapadon  
 
Confidential  Page 57 of 90 Version  4.0: 06 Jul 2023    
10 SUPPORTING DOCUMENTA TION AND OPERATIONAL  
CONSIDERATIONS  
10.1 Appendix 1: Regulatory, Ethical, and Trial Oversight Considerations  
10.1.1  Regulatory and Ethical Considerations  
This trial will be conducted in accordance with the protocol and with the following:  
• Consensus ethical principles derived from international guidelines including the 
Declaration of Helsinki and Council for International Organizations of Medical 
Sciences (CIOMS)  International Ethical Guidelines  
• Applicable International Conference on Harmonisation (ICH) GCP Guidelines  
• Applicable laws and regulations  
The protocol, protocol amendments, ICF, Investigator Brochure, and other relevant 
documents (eg, advertisements) mus t be submitted to an IRB/IEC by [CONTACT_31846]/IEC before the trial is initiated. Any amendments to 
the protocol will require IRB/IEC approval before implementation of changes made to 
the trial design, except for chan ges necessary to eliminate an immediate hazard to trial 
subjects.  
The investigator will be responsible for the following:  
• Providing written summaries of the status of the trial to the IRB/IEC annually or 
more frequently in accordance with the requirements,  policies, and procedures 
established by [CONTACT_1201]/IEC  
• Notifying the IRB/IEC of SAEs/AESI or other significant safety findings as required 
by [CONTACT_1744]/IEC procedures  
• Providing oversight of the conduct of the trial at the site and adherence to 
requirements of 21 Code of Federal Regulations (CFR), ICH guidelines, the 
IRB/IEC, European regulation 536/2014 for clinical trials (if applicable), and all 
other applicable local regulations  
10.1.2  Financial Disclosure  
Investigators and sub -investigators will provide the sponsor w ith sufficient, accurate 
financial information as requested to allow the sponsor to submit complete and accurate 
financial certification or disclosure statements to the appropriate regulatory authorities. 
Investigators are responsible for providing informa tion on financial interests during the 
course of the trial and for 1 year after completion of the trial.  
  
Protocol CVL -751-PD-003 
Tavapadon  
 
Confidential  Page 58 of 90 Version  4.0: 06 Jul 2023    
10.1.3  Informed Consent Process  
The investigator or his/her representative will explain the nature of the trial to the subject 
or his/her legally authorized r epresentative (as defined per local regulations) and answer 
all questions regarding the trial.  
Subjects must be informed that their participation is voluntary. Subjects or their legally 
authorized representative as applicable by [CONTACT_526412] a statement 
of informed consent (either electronic or written) that meets the requirements of [ADDRESS_683198] (HIPAA) requirements, where applicable, and the IRB/IEC or trial center.  
The medical record must include a statement that informed consent was obtained before 
the subject was enrolled in the trial and the date the consent was obtained. The authorized 
person obtaining the informed consent must also sign the ICF.  
Subjects must be reconsented to the most current version of the ICF(s) during their 
participation in the trial. A copy of the ICF(s) must be provided to the subject or the 
subject’s legally authorized representative (as defined per local regulations) .  
A separate and similar consent process will be followed for the optional banked 
biospecimen research samples. The investigator or authorized designee will explain  the 
objectives of the exploratory research to each subject. Subjects will be told that they ar e 
free to refuse to participate and may withdraw their consent at any time and for any 
reason during the storage period. A separate signature [CONTACT_330239]. Subjects wh o 
decline to participate in this optional research will not provide this separate signature.  
10.1.[ADDRESS_683199] records or 
datasets that are transferred to the sponsor will contain the identifier only; subject names 
or any information which would make the subject identifiable will not be transferred.  
The subject must be informed that his/her personal trial -related data will be used by [CONTACT_20004]. The level of disclosure must also be 
explained to the subject.  
The subject must be informed that his/her medical records may be examined by [CONTACT_11000], by 
[CONTACT_6667]/ IEC members, and by [CONTACT_6668].  
10.1.5  Dissemination of Clinical Trial Data  
Cerevel fulfills its commitment to publicly disclose clinical trial results through posting 
trial results on ClinicalTrials.gov, the European Clinical Trials D atabase (EudraCT), and 
other public registries in accordance with applicable local laws/regulations.  
  
Protocol CVL -751-PD-003 
Tavapadon  
 
Confidential  Page 59 of 90 Version  4.0: 06 Jul 2023    
In all cases, trial results are reported by [CONTACT_308711], accurate, balanced, and 
complete manner and are reported regardless of trial outcome o r the country in which the 
trial was conducted.  
US Basic Results are posted on Clinicaltrials.gov for all Cerevel -sponsored interventional 
trials that are conducted in subjects and that evaluate the safety and/or efficacy of a 
Cerevel product, regardless o f the geographical location in which the trial is conducted. 
US Basic Results are submitted for posting within 1  year of the primary completion date, 
as defined in Section  4.4, for trials in adult populations or within 6 months of the primary 
completion date for trials in pediatric populations.  
Cerevel posts European Union (EU) Basic Results on EudraCT for all Cerevel -sponsored 
interventional trials tha t are in scope of EU requirements. EU Basic Results are submitted 
for posting within [ADDRESS_683200] data relating to the trial will be recorded on printed or eCRFs unless 
transmitted to the sponsor or designee electronically (eg, laboratory data). The 
investigator is responsible for verifying that data entries are accurate and correct by 
[CONTACT_46388].  
The investigator must maintain accurate documentation (source data) th at supports the 
information entered in the eCRF.  
The investigator must permit trial -related monitoring, audits, IRB/IEC review, and 
regulatory agency inspections and provide direct access to source data documents.  
Monitoring details describing strategy (eg , risk -based initiatives in operations and quality 
such as Risk Management and Mitigation Strategies and Analytical Risk -Based 
Monitoring), methods, responsibilities, and requirements, including handling of 
noncompliance issues and monitoring techniques (c entral, remote, or on -site monitoring) 
are provided in the Clinical Monitoring Plan.  
The sponsor or designee is responsible for the data management of this trial including 
quality checking of the data.  
The sponsor assumes accountability for actions delegat ed to other individuals (eg, 
Contract Research Organizations).  
Trial monitors will perform ongoing source data verification to confirm that data entered 
onto the eCRF by [CONTACT_1191], complete, and verifiable from 
source documents ; that the safety and rights of subjects are being protected; and that the 
trial is being conducted in accordance with the currently approved protocol and any other 
trial agreements, ICH GCP, and all applicable regulatory requirements.  
  
Protocol CVL -751-PD-003 
Tavapadon  
 
Confidential  Page 60 of 90 Version  4.0: [ADDRESS_683201] of the following periods:  
• At least 2 years after the date on which approval to market the drug is obtained (or if 
development of the IMP is discontinued, the date regulatory authorities were notified 
of discontinuation  
• At least 3 years after the sponsor has notified the investigator that the final report has 
been filed with regulatory authorities  
• A longer period if required by [CONTACT_526413]. No records may be transferred to another location or party without written 
notification to the sponsor.  
10.1.[ADDRESS_683202] and substantiate the 
integrity of the data collected. Source documents are filed at the investigator’s site.  
Data entered in the eCRF that are transcribed from source documents must be consis tent 
with the source documents or the discrepancies must be explained. The investigator may 
need to request previous medical records or transfer records, depending on the trial. Also, 
current medical records must be available.  
Definitions of what constitut es source data are included in the Clinical Monitoring Plan.  
10.1.[ADDRESS_683203] been collected and a trial -site closure visit has been performed.  
The investigator may initiate trial -site closure at any time, provided th ere is reasonable 
cause and sufficient notice is given in advance of the intended termination.  
Reasons for the early closure of a trial site by [CONTACT_215887]:  
• Failure of the investigator to comply with the p rotocol, the requirements of the 
IRB/IEC or local health authorities, the sponsor's procedures, or GCP guidelines  
• Inadequate recruitment of subjects by [CONTACT_093]  
• Discontinuation of further trial intervention development  
  
Protocol CVL -751-PD-003 
Tavapadon  
 
Confidential  Page 61 of 90 Version  4.0: [ADDRESS_683204] editorial and ethical practice, the sponsor will generally support 
publication of multicenter trials only in their entirety and not as individual site data. In 
this case, a coordinating investigator [INVESTIGATOR_12992].  
Authorship will be determined by [CONTACT_14346].  
  
Protocol CVL -751-PD-003 
Tavapadon  
 
Confidential  Page 62 of 90 Version  4.0: 06 Jul 2023    
10.2 Append ix 2: Clinical Laboratory Tests  
The tests detailed in Table  11 will be performed at the time points designated in the 
Schedule of Assessments ( Table  2). Additional tests may be performed at any time during 
the trial as determined necessary by [CONTACT_11006]. .  
Table  11 Protocol -Required Safety Laboratory Assessments  
Laboratory 
Assessments  Parameters  
Hematology  Platelet count  
RBC count  
Hemoglobin  
Hematocrit  
MCV  WBC count with 
differential:  
Neutrophils  
Lymphocytes  
Monocytes  
Eosinophils  
Basophils   
Chemistry  BUN  
Creatinine  
Albumin  
Cholesterol  
Total  
HDL -C 
LDL -C 
Triglycerides  Potassium  
Sodium  
Calcium  
Bicarbonate  
Chloride  
Magnesium  
Glucose  ALT  
AST  
Alkaline phosphatase  
GGT  
CPK  
Total bilirubin  
Direct bilirubin  
Total protein  
TSH (with reflex -free 
T3/T4 i f abnormal)  
Urinalysis Specific gravity  
Color  Dipsticka 
pH 
Glucose  
Protein  
Blood  
Ketones  
Bilirubin  
Urobilinogen  
Nitrite  
Leukocyte esterase   
Additional 
Tests  Prolactin (results will not be reported to investigative sites or other blinded personnel 
until the trial is unblinded).  
Serum pregnancy test (at screening and as needed for WOCBP).  
Urine dipstick pregnancy test (at all other time points as needed for WOCBP), followed 
by [CONTACT_330230].  
If serum CPK value is > 3 × ULN, CPK reflex for isoenzymes.  
If serum CPK value is >5 × ULN, serum and urine myoglobin.  
  
Protocol CVL -751-PD-003 
Tavapadon  
 
Confidential  Page 63 of 90 Version  4.0: 06 Jul 2023    
Table  11 Protocol -Required Safety Laboratory Assessments  
Laboratory 
Assessments  Parameters  
Screening Tests  Urine drug screen for illicit drugs  
Serology (HIV, HbsAg, and HCV)  
Abbreviations: AE = adverse event, ALT  = alanine aminotransferase, AST  = aspartate aminotransferase, 
BUN  = blood urea nitrogen, CPK  = creatine phosphokinase, eCRF = electronic case report from, 
GGT  = gamma -glutamyl transferase, HbsAg  = hepatitis B surface antigen, HCV  = hepatitis  C virus, 
HDL -C = high-density lipoprotein cholester ol, HIV  = human immunodeficiency virus, 
LDL -C = low-density lipoprotein cholesterol, MCV  = mean corpuscular volume, RBC  = red blood cell, 
T3 = triiodothyronine, T4  = thyroxine, TSH  = thyroid -stimulating hormone, ULN  = upper limit of normal, 
WBC  = white blo od cell, WOCBP  = women of childbearing potential.  
a. Results of the dipstick urine analysis will not be recorded on the eCRFs. Any clinically significant 
finding will be captured as an AE.  
Investigators must document their review of each laboratory safety report and file the 
laboratory report as appropriate. Any clinically significant laboratory abnormality must 
be reported as an AE.  
 
  
Protocol CVL -751-PD-003 
Tavapadon  
 
Confidential  Page 70 of 90 Version  4.0: 06 Jul 2023    
10.4 Appendix 4: Contraceptive Guidance and Collection of Pregnancy 
Information  
10.4.1  Definitions  
[IP_ADDRESS]  Highly Effective Birth Control Methods (Failure Rate <1%)  
A highly effective form of contraception (failure rate of <1%) is defined as follows:  
• Combined (estrogen and progestogen containing) hormonal contraception associated 
with inhibition of ovulation:  
• Oral 
• Intravaginal  
• Transdermal  
• Progestogen -only hormonal contraception associated with inhibition of ovulation:  
• Oral 
• Injectable  
• Implantable  
• Intrauterine device  
• Intrauterine hormone -releasing system  
• Bilateral tubal occlusion  
• Vasectomized partner  
• Sexual abstinence is considered a highly effective method only if defined as 
refraining from heterosexual intercourse during the  entire period of risk associated 
with the trial treatments. The reliability of sexual abstinence needs to be evaluated in 
relation to the duration of the clinical trial and the preferred and usual lifestyle of the 
subject.  
[IP_ADDRESS]  Acceptable Birth Control Methods  (Failure Rate >1% per Year)  
Acceptable birth control methods that result in a failure rate of more than 1% per year 
include:  
• Progestogen -only oral hormonal contraception, where inhibition of ovulation is not 
the primary mode of action  
• Male or female condom with or without spermicide*  
• Cap, diaphragm or sponge with spermicide.* 
*A combination of male condom with a cap, diaphragm, or sponge with spermicide 
(double -barrier methods) is also considered acceptable but is not a highly effectiv e birth control 
method.  
  
Protocol CVL -751-PD-003 
Tavapadon  
 
Confidential  Page 71 of 90 Version  4.0: 06 Jul 2023    
[IP_ADDRESS]  Contraception and Pregnancy Avoidance Procedures  
The following definitions apply for contraception and pregnancy avoidance procedures:  
A woman is considered to be a woman of childbearing potential (WOCBP) following 
menarche and unti l becoming postmenopausal unless permanently sterile. Permanent 
sterilization methods include hysterectomy and bilateral oophorectomy.  
A postmenopausal state is defined as no menses for [ADDRESS_683205] had bilateral orchidectomy.  
10.4.2  Collection of Pregnancy Information  
[IP_ADDRESS]  Male Subjects With Partners Who B ecome Pregnant  
• The investigator will attempt to collect pregnancy information on any male subject’s 
female partner who becomes pregnant while the male subject is in this trial. This 
applies only to male subjects who receive trial intervention.  
• After obtain ing the necessary signed informed consent from the pregnant female 
partner directly, the investigator will record pregnancy information on the 
appropriate form and submit it to the sponsor within 24 hours of learning of the 
partner’s pregnancy. The female partner will also be followed to determine the 
outcome of the pregnancy. Information on the status of the mother and child will be 
forwarded to the sponsor. Generally, the follow -up will be no longer than 6 to 
8 weeks following the estimated delivery date.  Any termination of the pregnancy 
will be reported regardless of fetal status (presence or absence of anomalies) or 
indication for the procedure.  
[IP_ADDRESS]  Female Subjects Who Become Pregnant  
• The investigator will collect pregnancy information on any female subject  who 
becomes pregnant while participating in this trial. Information will be recorded on 
the appropriate form and submitted to the sponsor within [ADDRESS_683206]'s pregnancy.  
• The subject will be followed to determine the outcome of the p regnancy. The 
investigator will collect follow -up information on the subject and the neonate and the 
information will be forwarded to the sponsor. Generally, follow -up will not be 
required for longer than 6 to 8 weeks beyond the estimated delivery date. An y 
termination of pregnancy will be reported, regardless of fetal status (presence or 
absence of anomalies) or indication for the procedure.  
• While pregnancy itself is not considered to be an AE or SAE, any pregnancy 
complication or elective termination of a  pregnancy will be reported as an AE or 
  
Protocol CVL -751-PD-003 
Tavapadon  
 
Confidential  Page 72 of 90 Version  4.0: [ADDRESS_683207] -trial pregnancy related SAE considered reasonably 
related to the trial intervention by [CONTACT_526414]  8.4.4 . While the investigator is not obligated to actively seek 
this information in former trial subjects, he or she may learn of an SAE through 
spontaneous reporting.  
• Any female subject who becomes pregnant while participating in the trial will 
discontinue trial intervention and be withdrawn from the trial.  
  
Protocol CVL -751-PD-003 
Tavapadon  
 
Confidential  Page 73 of 90 Version  4.0: 06 Jul 2023    
10.5 Appendix 5: Future Biospecimen Research  
Use/Analysis of DNA  
• Genetic variation may impact a subject’s response to trial intervention, susceptibility 
to, and severity and progression of disease. Variable response to trial intervention 
may be due to genetic determinants that impact drug absorption, di stribution, 
metabolism, and excretion; mechanism of action of the drug; disease etiology; and/or 
molecular subtype of the disease being treated. Therefore, where local regulations 
and IRB/IEC allow, a blood sample will be collected for DNA analysis from 
consenting subjects.  
• DNA samples will be used for research related to tavapadon or PD and related 
diseases. They may also be used to develop tests/assays, including diagnostic tests 
related to tavapadon and PD. Genetic research may consist of the analysis of  one or 
more candidate genes or the analysis of genetic markers throughout the genome or 
analysis of the entire genome (as appropriate).  
• DNA samples will be analyzed as part of a multi -trial assessment of the genetic 
factors that are involved in response t o tavapadon or IMPs of this class to understand 
the trial disease or related conditions  
• The results of genetic analyses may be reported in the CSR or in a separate trial 
summary.  
• The sponsor will store the DNA samples in a secure storage space with adequat e 
measures to protect confidentiality.  
• The samples will be retained while research on tavapadon continues but for no 
longer than 15  years or other period as per local requirements.  
  
Protocol CVL -751-PD-003 
Tavapadon  
 
Confidential  Page 74 of 90 Version  4.0: 06 Jul 2023    
10.6 Appendix  6: Examples of Moderate and Strong Inducers and 
Inhibitors of Cytochrome P450 3a (CYP3A)  
Table 19 Examples of Moderate and Strong Inducers and Inhibitors of 
CYP3A  
CYP3A Inhibitors  CYP3A Inducers  
HIV antivirals  HIV antivirals  
Indinavir  Efavirenz  
Nelfinavir  Nevirapi[INVESTIGATOR_330187]/ritonavir  Carbamazepi[INVESTIGATOR_330188] (systemic)  
Atazanavir  Modafinil  
Telaprevir  Oxcarbazepi[INVESTIGATOR_330189]/ritonavir  Phenobarbital  
Fosamprenavir  Phenytoin  
Antibiotics  Pi[INVESTIGATOR_330190]. John’s wort  
Ciprofloxacin  Troglitazone  
Anti -infectives  Bosentan  
Itraconazole  Nafcillin  
Ketoconazole  Avasimibe  
Fluconazole   
Posaconazole   
Voriconazole   
Anti -anginal therapy   
Diltiazem   
Verapamil   
Anti -cancer therapy   
Crizotinib   
Imatinib   
  
Protocol CVL -751-PD-003 
Tavapadon  
 
Confidential  Page 75 of 90 Version  4.0: 06 Jul 2023    
Table 19 Examples of Moderate and Strong Inducers and Inhibitors of 
CYP3A  
CYP3A Inhibitors  CYP3A Inducers  
Miscellaneous   
Nefazodone   
Aprepi[INVESTIGATOR_526403],b  
Conivaptan   
Mibefradilc  
Abbreviations: CYP  = cytochrome P450, HIV  = human immunodeficiency virus.  
a. The effect of grapefruit juice varies widely among brands and is concentration -, dose -, and 
preparation -dependent.  Trials have shown that it can be classified as a “strong CYP3A inhibitor” 
when a certain preparation was used (eg, hi gh dose, double strength) or as a “moderate CYP3A 
inhibitor” when another preparation was used (eg, low dose, single strength).  
b. A 2-week washout before dosing is required if the subject was consuming grapefruit juice 
continually.  
c. Withdrawn from US market.  
  
Protocol CVL -751-PD-003 
Tavapadon  
 
Confidential  Page 76 of 90 Version  4.0: 06 Jul 2023    
10.7 Appendix 7: Abbreviations  
 
Abbreviation  Definition  
AE Adverse event  
Aetau Amount of unchanged drug excreted into the urine over a dosing interval (tau) at 
steady state  
AESI  Adverse event of special interest  
ALT  Alanine aminotransferase  
APMP  Abuse Potential Monitoring Plan  
AST  Aspartate aminotransferase  
BUN  Blood urea nitrogen  
Cmax Maximum observed plasma concentration  
cAMP  Cyclic adenosine monophosphate  
CFR  Code of Federal Regulations  
CI Confidence interval  
CIOMS  Council for International Organizations of Medical Sciences  
COMT  Catechol -O-methyltransferase  
CONSORT  Consolidated Standards of Reporting Trials  
CPK  Creatine phosphokinase  
CRF  Case report form  
CSR  Clinical study report  
C-SSRS  Columbia -Suicide Severity Rating Scale  
CVL -751 Tavapadon  
D1Rs  Dopamine D1 -like receptors  
D2/D3R  Dopamine D2 and D3 receptor subtypes  
DNA  Deoxyribonucleic acid  
DSM -[ADDRESS_683208] to additional monitoring  
ESS Epworth Sleepi[INVESTIGATOR_526404] -751-PD-003 
Tavapadon  
 
Confidential  Page 77 of 90 Version  4.0: [ADDRESS_683209]  
ITT Intent -to-treat 
IVRS/IWRS  Interactive Voice Response System/Interactive Web Response System  
LDL -C Low-density lipoprotein cholesterol  
L-Dopa  Levodopa  
LSMean  Least square mean  
MAO  Monoamine oxidase  
MAO -B Monoamine oxidase B  
MCV  Mean corpuscular volume  
MDS -UPDRS  Movement Disorder Society – Unified Parkinson’s Disease Rating Scale  
MedDRA  Medical Dictionary for Regulatory Activities  
MHIs  Medication handling irregularities  
mITT  Modified intent -to-treat 
MMRM  Mixed Model for Repeated Measures  
MoCA  Montreal Cognitive Assessment  
PD Parkinson’s disease  
PDQ -39 39-Item Parkinson’s Disease Questionnaire  
  
Protocol CVL -751-PD-003 
Tavapadon  
 
Confidential  Page 78 of 90 Version  4.0: 06 Jul 2023    
Abbreviation  Definition  
PF-0664975  Previous laboratory code for tavapadon  
PK Pharmacokinetic  
QD Once daily  
QTcF  QT interval corrected for heart rate by [CONTACT_6550]’s formula  
QUIP -RS Questionnaire for Impulsive -Compulsive Disorders in Parkinson’s Disease – 
Rating Scale  
RBC  Red blood cell  
RNA  Ribonucleic acid  
SAE  Serious adverse event  
S[LOCATION_003]R  Suspected unexpected serious adverse reaction  
T3 Triiodothyronine  
T4 Thyroxine  
TEAE  Treatment -emergent adverse event  
THC  Tetrahydrocannabinol  
TSH  Thyroid -stimulating hormone  
ULN  Upper limit of normal  
VAS  Visual analog scale  
WBC  White blood cell  
WOCBP  Women of childbearing potential  
  
Protocol CVL -751-PD-003 
Tavapadon  
 
Confidential  Page 79 of 90 Version  4.0: 06 Jul 2023    
10.8 Appendix  8: Protocol Amendment History  
Document History  
Document:  Date (Day -Month -Year)  
Version 4.[ADDRESS_683210] 2019  
The Protocol Amendment Summary of Changes Table for the current amendment is 
located directly before the Table of Contents.  
Amendment: Protocol Version 3.0 (03 Sep  2021)  
This amendment is considered to be substantial based on the criteria set forth in Article 
10(a) of Directive 2001/20/EC of the European Parliament and the Council of the 
European Union.  
Overall Rationale for the Amendment: The overall rationale for this amendment is to 
correct errors and to harmonize similar content across the Phase 3 tavapadon protocols 
via modification and clarification of eligibility criteria, procedural aspects, and statistical 
considerations.  
Section # and Name  [CONTACT_526419] 
[INVESTIGATOR_330192]  
1.1 Synopsis  
3 OBJECTIVES AND 
ENDPOINTS  Objectives and Endpoints tables:  
Changed metabolites to singular 
(metabolite)  Correction of error in protocol  
1.1 Synopsis  
 Statistical Methods:  
Added details regarding analysis of 
efficacy endpoints  Alignment with corresponding 
content in current statistical 
analysis plan  
9 STATISTICAL 
CONSIDERATIONS  Clarified analyses associated with 
each analysis set 
Added details regarding analysis of 
efficacy endpoints   
1.2 Schema  Hauser Diary:  
Added text to specify completion 
“within 7 days” before each clinic 
visit Consistency with diary 
completion instructions in 
Schedule of Assessments and 
Hauser Diary sections  
  
Protocol CVL -751-PD-003 
Tavapadon  
 
Confidential  Page 80 of 90 Version  4.0: 06 Jul 2023    
Section # and Name  [CONTACT_11029]  
1.[ADDRESS_683211] of single measurement  Correction of error in protocol  
1.3 Schedule of Assessments 
(continued)  Revised table to  indicate that 
medical occurrences before the start 
of IMP dosing but after obtaining 
informed consent will be recorded 
as medical and/or psychiatric history 
and that AEs will be recorded from 
the first dose of IMP  Clarification of recording 
timeframes relative to informed 
consent and first dose of IMP  
 Clarified ECG footnote language 
about timing of postbaseline PK 
samples relative to ECG 
assessments  Consistency with Section 8.6  
Pharmacokinetics  
4.1.2 Treatment Period  Added the following and deleted 
redundant text:  
Titration of tavapadon should be 
guided by [CONTACT_330232]. Any 
questions regarding tolerability 
issues and titration of tavapadon 
should be directed to the medical 
monitor before adjustments are 
initiated.  To emphasize that titration of 
tavapadon should be related to 
tolerability issues and to further 
define tolerability issues  
4.[ADDRESS_683212] at the end 
of the Safety Follow -up Period to 
the end of the Treatment Period 
(Week 27)  Consistency with other sponsor 
protocols that define completed 
subject according to last site 
visit rather than the final contact  
  
[CONTACT_526415] -751-PD-003 
Tavapadon  
 
Confidential  Page 81 of 90 Version  4.0: 06 Jul 2023    
Section # and Name  [CONTACT_11029]  
5.1 Inclusion Criteria  Inclusion Criterion #5:  
Deleted the following  
...with bradykinesia and motor 
asymmetry  
Note: Motor asymmetry may or may 
not be present at the time of 
Screening, and is not an explicit 
requirement for inclusion, as long as 
the subject meets the [LOCATION_006] 
Parkinson’s Disease Society Brain 
Bank diagnostic criteria based on 
medical history or physical 
examination.  Clarification regarding presence 
of motor asymmetry with 
respect to inclusion criteria  
 Added the following:  
Note: Subjects having more than 
one affected relative (Step 2 [LOCATION_006] 
Parkinson’s Disease Society Brain 
Bank exclusion criterion) but 
meeting all other criteria consistent 
with the [LOCATION_006] criteria will be 
considered to have met eligibility 
criteria f or a diagnosis of PD 
(Litvan et al, 2003; Massano and 
Bhatia, 2012).  Consistency with utilization of 
the historical [LOCATION_006] criteria in 
current clinical practice, which 
no longer considers having more 
than one affected relative 
exclusory of a diagnosis of 
idiop athic PD based on the more 
recent understanding of the 
complex contributory genetic 
factors  
 Inclusion Criterion #7:  
Added note that subjects receiving 
levodopa/carbidopa intestinal gel are 
not eligible  Clarification of eligibility 
criteria; inclusion cri teria 
specify requirement of good 
response to levodopa, whereas 
levodopa/carbidopa intestinal 
gel is indicated for use when 
available combinations of 
Parkinson’s treatments 
medicinal products have not 
yielded satisfactory results  
 Inclusion Criterion #10:  
Added istradefylline as a permitted 
prior or concomitant medication  To reflect health authority 
approval and increase in 
common usage as adjunctive 
treatment in Parkinson’s disease  
5.1 Inclusion Criteria  
6.5.2 Allowed Medications 
Before and During the Tr ial Added language to allow use of 
levodopa/benserazide  Levodopa/benserazide is an 
acceptable alternative to 
levodopa/carbidopa that is 
commonly used in some 
countries where this trial is 
being conducted  
  
Protocol CVL -751-PD-003 
Tavapadon  
 
Confidential  Page 82 of 90 Version  4.0: 06 Jul 2023    
Section # and Name  [CONTACT_11029]  
5.1 Inclusion Criteria  
6.5.3 Prohibited Medications  
Before the Trial  Changed timing of treatment with 
COMT inhibitors, MAO -B 
inhibitors, amantadine, and 
anticholinergic drugs to be relative 
to Baseline Visit rather than signing 
of informed consent  Correction to be consistent with 
other sponsor protocols th at 
define timing of washout periods 
for prohibited medications 
relative to the Baseline Visit  
5.2 Exclusion Criteria  Exclusion Criterion #12:  
Added the following:  
Note: Subjects who were previously 
infected with hepatitis C but have 
been successfully trea ted (defined as 
a sustained virologic response or 
undetectable hepatitis C viral RNA 
levels at 12 or more weeks after the 
end of treatment) may be enrolled 
after discussion with the medical 
monitor.  Consistency with other sponsor 
protocols that allow enrol lment 
of subjects with history of 
hepatitis C that has been 
successfully treated  
5.[ADDRESS_683213] dose of IMP  
6.5.3 Prohibited Medications 
Before the  Trial  Added istradefylline to item that 
includes COMT inhibitors, MAO -B 
inhibitors, amantadine, and 
anticholinergic drugs  Alignment with change to 
Inclusion Criterion #10 and to 
define washout, if required  
6.5.3 Prohibited Medications 
Before the Trial  
6.5.4 Prohibited Medications 
During the Trial  Added levodopa inhalation powder 
to prohibited medications  
Added apomorphine as a prohibited 
medication (ie, in the dopamine 
agonist rows of the corresponding 
tables)  Clarification regarding rescue 
therapi[INVESTIGATOR_526405] (eg, pregabalin) if 
approved by [CONTACT_330235]  
6.5.4 Prohibited Medications 
During the Trial  Combined separate items for 
sedatives, hypnotics, 
antidepressants, anxiolytics into 
single item  Consistency with table of 
medications prohibited before 
the trial  
 Added text to allow short -term use 
of lorazepam (or equivalent) if 
approved by [CONTACT_526416] -term use 
of scopolamine if approved by [CONTACT_526417] -751-PD-003 
Tavapadon  
 
Confidential  Page 83 of 90 Version  4.0: 06 Jul 2023    
Section # and Name  [CONTACT_11029]  
6.5.4 Prohibited Medications 
During the Trial (continued)  Added the following:  
COMT inhibitors, MAO -B 
inhibitors, amantadine, 
istradefylline, or anticholinergic 
drugs (unless use was initiated >90 
days before the Baseline Visit and 
dose will remain stable for the 
duration of the treatment phase)  Consistency with Table 6 
(medications prohibited before 
the trial) and convention used 
for sedatives, hypnotics, 
antidepressants, and anxiolytics 
in the table of medications 
prohibited during the trial  
7.[ADDRESS_683214] discontinuation of IMP  To align more closely with 
eCRF  
8.1 Screening and Baseline 
Assessments  Added the following:  
Data collected as part of the 
screening process may be submitted 
to sponsor/clinical research 
organization (CRO) in order to 
facilitate eligibility assessment.  To address recent regulatory 
updates observed during trial 
conduct  
8.3.[ADDRESS_683215] of single measurement  Alignment across Phase 3 
protocols and consistency with 
changes to Section 1.3  
8.4.1 Time Period and 
Frequency for Collecting AE 
and SAE/AESI Information  Clarified that AEs will be recorded 
from the first dose of IMP and 
medical occurrences that begin 
before the start of IMP dosing but 
after obtaining informed consent 
will be recorded as medical and/or 
psychiatric history  Confirm timeframes for medical 
history and AE recording 
relative to informed consent and 
first dose of IMP  
10.3.3 Recording and 
Follow -Up of AEs and/or 
SAEs/AESI  Deleted the following language:  
...that are identified at any time 
during the trial...  
...having been identified thr oughout 
the trial...  Alignment with changes to 
language about AE recording 
starting from first dose of IMP  
11 REFERENCES  Added new references:  
Litvan et al, [ADDRESS_683216] revision to Inclusion 
Criterion #5  
Overall  Corrections/clarifications o f 
grammar or typographical errors  To address minor errors in the 
previous version of the protocol  
Abbreviations: AE = adverse event, AESI = adverse event of special interest, COMT = catechol -O-methyl 
transferase, eCRF = electro nic case report form, ECG = electrocardiogram, IMP = investigational 
medicinal product, MAO -B = monoamine oxidase inhibitor B, PD = Parkinson’s disease, PK = 
pharmacokinetic, RNA = ribonucleic acid, SAE = serious adverse event.  
Amendment: Protocol Version 2.0 (29  Jun 2020)  
  
Protocol CVL -751-PD-003 
Tavapadon  
 
Confidential  Page 84 of 90 Version  4.0: 06 Jul 2023    
This amendment is considered to be substantial based on the criteria set forth in Article 
10(a) of Directive 2001/20/EC of the European Parliament and the Council of the 
European Union.  
Overall Rationale for the Amendment:  
The overall rat ionale for this amendment is to incorporate measures into the protocol to 
ensure the safety of the trial subjects and the validity of the trial data in the environment 
of the COVID -[ADDRESS_683217] unrelated to the 
COVID -19 pandemic.  
 
Section # and Name  [CONTACT_330240]  
1.1, Synopsis (Statistical 
Methods)  
9.2, Sample Size Determination  Added provision to extend 
enrollment to maintain the 
planned statistical power in the 
event of higher than expected 
early terminations due to 
COVID -[ADDRESS_683218]  
2.3, Benefit/Risk Assessment  Added a statement that, in 
response to the COVID -[ADDRESS_683219]  
  
Protocol CVL -751-PD-003 
Tavapadon  
 
Confidential  Page 85 of 90 Version  4.0: 06 Jul 2023    
Section # and Name  [CONTACT_11029]  
5.1, Inclusion Criteria  Modified the wording related to 
use of contraceptives in 
inclusion criterion #2  Clarify contraceptive 
requirement  
5.2, Exclusion Criteria  Modified the wording related to 
current and prior use of 
prohibited medications in 
exclusion criterion #19  Simplify language by [CONTACT_330236] 
(Table  6) and during (Table  7) 
the trial  
 Modified the wording of 
exclusion criterion #[ADDRESS_683220] lack of clarity 
surrounding duplicate readings 
and the value that should be used 
to assess trial eligibility  
 Expanded exclusion criteria 
related to prolonged QTcF 
interv al in exclusion criterion 
#23  Align exclusion criterion with 
methods for obtaining ECGs in 
Section  8.3.6  
 Clarified the process to be 
followed for subjects with 
medically significant or 
exclusionary abnormal ECG 
results in exclusion criterion #26  Align e xclusion criterion with 
methods for obtaining ECGs in 
Section  8.3.6  
6.5.3, Prohibited Medications 
Before the Trial  Added use of COMT inhibitors, 
MAO -B inhibitors, amantadine, 
or anticholinergic drugs 
<90 days before signing ICF and 
washout period to Table  6 Align information in table with 
inclusion criterion #10  
6.5.4, Prohibited Medications 
During the Trial  Changed “stable for the duration 
of the trial” to “stable for the 
duration of the treatment phase” 
in entries 1, 2, 5, and [ADDRESS_683221]  
10.1.3, Informed Consent 
Process  Added language to specify that 
individuals who are considered 
to be a “legal representative” for 
the subject will be defined per 
local regulations  Clarify term, which may differ 
among regions in which the trial  
is conducted  
8.3.5, Vital Signs  Modified the section to specify 
that individual values from 
duplicate blood pressure and 
heart rate readings will be 
averaged by [CONTACT_526418] -751-PD-003 
Tavapadon  
 
Confidential  Page 86 of 90 Version  4.0: 06 Jul 2023    
Section # and Name  [CONTACT_11029]  
8.3.6, Electrocardiograms  Modified the section to provide 
additional information related to 
ECG collection  Clarify the processes for 
acquiring ECGs at the Screening 
and Baseline Visits  
10.2, Appendix  2: Clinical 
Laboratory Tests  Specified the urine pregnancy 
test as a urine dipstick test in 
Table [ADDRESS_683222]  
10.3, Appendix  3: Adverse 
Events: Definitions and 
Procedures for Recording, 
Evaluating, Follow -up, and 
Reporting  Revised section to remove 
redundant language and to 
clarify AE/SAE/AESI reporting 
procedures  Align wording with ac tual 
processes that will be followed 
in trial and for consistency 
across Cerevel clinical 
development programs  
10.4, Contraceptive Guidance 
and Collection of Pregnancy 
Information  Revised title of Section  [IP_ADDRESS]  Consistency across Cerevel 
clinical development programs  
10.8, Appendix 8: Protocol 
Amendment History  Added section  Consistency with corporate 
template  
Overall  Minor grammatical corrections  Correct minor errors in the 
previous version of the protocol  
Abbreviations: AE = adverse event, AES I = adverse event of special interest, COMT = catechol -O-methyl 
transferase, ICF = informed consent form, MAO -B = monoamine oxidase inhibitor B, SAE  = serious 
adverse event.  
 
  
Protocol CVL -751-PD-003 
Tavapadon  
 
Confidential  Page 87 of 90 Version  4.0: 06 Jul 2023    
11 REFERENCES  
American Psychiatric Association. Diagnostic and statistical manual of  mental disorders. 
5th ed. Arlington, VA: American Psychiatric Publishing; 2013.  
Binde CD, Tvete IF, Gåsemyr J, Natvig B, Klemp M. A multiple treatment comparison 
meta -analysis of monoamine oxidase type B inhibitors for Parkinson's disease. Br J Clin 
Pharm acol. 2018;84(9):1917 -27. 
Connolly BS, Lang AE. Pharmacologic treatment of Parkinson’s disease: a review. 
JAMA. 2014;11(16):1670 -83. 
de Rijk MC, Breteler MM, Graveland GA, et al. Prevalence of Parkinson's disease in the 
elderly: the Rotterdam Study. Neurol ogy. 1995;45(12):2143 -6. 
Dietrichs E, Odin P. Algorithms for the treatment of motor problems in Parkinson's 
disease. Acta Neurol Scand. 2017;136(5):[ADDRESS_683223] populous nations, 2005 through 2030. Neurology. 
2007;68(5):384 -6. 
Drutyte G, Forjaz MJ, Rodriguez -Blazquez C, Martinez -Martin P, Breen KC. What 
impacts on the stress symptoms of Parkinson's carers? Results from the Parkinson's [LOCATION_006] 
Members' Survey. Disabil Rehabil. 2014;36(3):199 -204. 
Goetz CG, Poewe W, Rascol O, Sampaio C, Stebbins GT, Counsell C, et al. Movement 
Disorder Society Task Force report on the Hoehn and Yahr staging scale: status and 
recommendations. Mov Disord. 2004;19(9):1020 -8. 
Goetz CG, Tilley BC, Shaftman SR, Stebbins GT, Fahn S, Martinez -Martin P, et al. 
Movement Disorder Society -sponsored revision of the Unified Parkinson's Disease 
Rating Scale (MDS -UPDRS): scale presentation and clinimetric testing results. Mov 
Disord. 2008 ;15;23(15):2129 -70. 
Hauser RA, Auinger P; Parkinson Study Group. Determination of minimal clinically 
important change in early and advanced Parkinson's disease. Mov Disord. 
2011;26(5):813 -8. 
Hauser RA, Friedlander J, Zesiewicz TA, Adler CH, Seeberger LC, O 'Brien CF, et al. A 
home diary to assess functional status in patients with Parkinson's disease with motor 
fluctuations and dyskinesia. Clin Neuropharmacol. 2000;23(2):75 -81. 
Hauser RA, Gordon MF, Mizuno Y, Poewe W, Barone P, Schapi[INVESTIGATOR_330194], et al. Minimal 
clinically important difference in Parkinson's disease as assessed in pi[INVESTIGATOR_330195]. Parkinsons Dis. 2014;2014:467131.  
  
Protocol CVL -751-PD-003 
Tavapadon  
 
Confidential  Page 88 of 90 Version  4.0: 06 Jul 2023    
Herdman M, Gudex C, Lloyd A, Janssen M, Kind P, Parkin D, et al. Development and 
preliminary testing of th e new five -level version of EQ -5D (EQ -5D-5L). Qual Life Res. 
2011; 20(10):1727 –36. 
Hoehn M, Yahr M. Parkinsonism onset, progression and mortality. Neurology. 
1967;17(5):[ADDRESS_683224]. 2015;21(12):1421 -6. 
Jasinska -Myga B, Heckman  MG, Wider C, Putzke JD, Wszolek ZK, Uitti RJ. Loss of 
ability to work and ability to live independently in Park inson's disease. Parkinsonism 
Relat Disord. 2012;18(2):130 -5. 
Johns MW. A new method for measuring daytime sleepi[INVESTIGATOR_008]: the Epworth sleepi[INVESTIGATOR_217073]. Sleep. 1991;14(6):540 -5. 
Litvan I, Bhatia KP, Burn DJ, et al. Movement Disorders Society Scientific Issues 
Committee report: SIC Task Force appraisal of clinical diagnostic criteria for 
Parkinsonian disorders. Mov Disord. 2003;18(5):467 -86. 
Makkos A, Kovács M, Aschermann Z, Harmat M, Janszky J, Karádi K, et al. Are the 
MDS -UPDRS -Based Composite Scores Clinicall y Applicable? Mov Disord. 
2018;33(5):835 -9. 
Marconi R, Lefebvre -Caparros D, Bonnet AM, Vidailhet M, Dubois B, Agid Y. 
Levodopa -induced dyskinesias in Parkinson's disease phenomenology and 
pathophysiology. Mov Disord. 1994;9(1):2 -12. 
Massano J, Bhatia KP. C linical approach to Parkinson's disease: features, diagnosis, and 
principles of management. Cold Spring Harb Perspect Med. 2012;2(6):a008870.  
Nasreddine ZS, Phillips NA, Bédirian V, Charbonneau S, Whitehead V, Collin I, et al. 
The Montreal Cognitive Assess ment, MoCA: a brief screening tool for mild cognitive 
impairment. J Am Geriatr Soc. 2005;53(4):695 -9. 
Peto V, Jenkinson C, Fitzpatrick R. PDQ -39: a review of the development, validation and 
application of a Parkinson's disease quality of life questionnaire  and its associated 
measures. J Neurol. 1998;245(Suppl 1):S10 -4. 
Posner K, Brown GK, Stanley B, Brent DA, Yershova KV, Oquendo MA, et al. The 
Columbia –Suicide Severity Rating Scale: Initial validity and internal consistency 
findings from three multisite st udies with adolescents and adults. Am J Psych. 
2011;168(12):1266 -1277.  
  
Protocol CVL -751-PD-003 
Tavapadon  
 
Confidential  Page 89 of 90 Version  4.0: 06 Jul 2023    
Rizek P, Kumar N, Jog MS. An update on the diagnosis and treatment of Parkinson 
disease. CMAJ. 2016;188(16):[ADDRESS_683225] s for the treatment 
of Parkinson's disease. Expert Opin Pharmacother. 2016;17(14):[ADDRESS_683226] therapy in early Parkinson’s 
disease. Cochrane Database Syst Rev. 2008 Apr 16;(2):CD006564.  
Twelves D, Perkins K S, Counsell C. Systematic review of incidence studies of 
Parkinson's disease. Mov Disord. 2003;18(1):19 -31. 
US Food and Drug Administration (FDA). Guidance for Industry: E10 choice of control 
group and related issues in clinical trials; May  2001.  
Vijayakum ar D, Jankovic J. Drug -induced dyskinesia, part 1: treatment of 
levodopa -induced dyskinesia. Drugs. 2016;76(7):759 -77. 
Weintraub D, Mamikonyan E, Papay K, Shea JA, Xie SX, Siderowf A. Questionnaire for 
Impulsive -Compulsive Disorders in Parkinson’s Disease -Rating Scale. MovDisord. 
2012;27(2):242 -7. 
Zhuo C, Zhu X, Jiang R, et al. Comparison for efficacy and tolerability among ten drugs 
for treatment of Parkinson's disease: A network meta -analysis. Sci Rep. 2017;8:[ZIP_CODE].  
  
Protocol CVL -751-PD-003 
Tavapadon  
 
Confidential  Page 90 of 90 Version  4.0: 06 Jul 2023    
CLINICAL PROTOCOL PRINCIPAL INVESTIGATO R 
SIGNATURE  [CONTACT_1783]  
A PHASE 3, DOUBLE -BLIND, RANDOMIZED, 
PLACEBO -CONTROLLED, PARALLEL -GROUP, 
FLEXIBLE -DOSE, 27 -WEEK TRIAL TO EVALUATE THE 
EFFICACY, SAFETY, AND TOLERABILITY OF TAVAPADON AS 
ADJUNCTIVE THERAPY FOR PARKINSON’S  DISEASE IN 
LEVODOPA -TREATED ADULTS  
WITH MOTOR FLUCTUATIONS (T EMPO-3 TRIAL)  
Protocol Number: CVL -751-PD-003 
Compound: Tavapadon (CVL -751) 
Trial Phase: 3  
Sponsor Name: [CONTACT_308719], LLC  
Legal Registered Address: [ADDRESS_683227], Cambridge, MA [ZIP_CODE] [LOCATION_003]  
Version 4.0: [ADDRESS_683228] this trial in accordance with the principles of Good Clinical Practice s and 
as described herein and in the sponsor’s (or designee’s) Clinical Research 
Agreement.  
 
 
 
 
Principal Investigator [INVESTIGATOR_308689] (DD MMM YYYY)  
 